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ABSTRACT
The influenza A virus (IAV) causes severe respiratory illness in humans. Current
treatments are rapidly becoming ineffective due to the emergence of viral resistance to
available therapies such as oseltamivir and zanamivir. Given the impact of this virus there
is an urgent need to explore novel targets for new treatments less susceptible to viral
mutation; targeting host proteins utilized by the virus may avoid these limitations. It has
been shown in vitro that interactions with host ER based protein disulfide isomerases
(PDIs) are required for specific IAV proteins to reach their functional conformations. The
viral proteins hemagglutinin (HA) and neuraminidase (NA) both contain numerous
disulfide bonds necessary for their functionality. Our results demonstrate both HA and NA
interact with host PDIA3; a chaperone responsible for the catalysis of disulfide bonds in
newly formed glycoproteins. However, it is unknown whether these host-viral protein
interactions are required during active infection and whether they represent a putative
therapeutic target for the treatment of influenza infection.
In this dissertation I investigated the role of host PDIA3 in the folding of IAV
proteins and development of subsequent immunopathology. The impact of PDIA3 during
both H1N1 and H3N2 influenza infection was examined using lung epithelial specific
PDIA3 knockout mice and inhibitors of PDIs in primary human bronchial epithelial cells
and isolated mouse tracheal epithelial cells. Among PDI inhibitors tested, we found
LOC14 inhibits PDIA3 at an IC50 of 5μM. Treatment with LOC14 inhibits PDIA3 activity
in lung epithelial cells and subsequently decreases disulfide bonds and oligomerization of
HA in both H1N1 and H3N2 infected primary lung epithelial cells. Biotin switch assays
indicated that LOC14 also decreased disulfide bonds in NA and these differences in
oxidative folding correspond to a subsequent decrease in NA activity. Furthermore,
following LOC14 treatment we observed a decrease in detectable viral protein in
supernatants from infected cells, suggesting potential deficiencies in viral release.
Moreover, these decreases in disulfide bonds significantly decrease viral load, and proinflammatory responses from primary lung epithelial cells. Lung epithelial specific
deletion of PDIA3 in mice results in a significant decrease in viral burden and levels of
inflammatory-immune markers in mouse lung, as well as significantly improved airway
mechanics. Additionally, in vivo administration of LOC14 partially mirrored these results,
yielding significant decreases in overall viral burden. Taken together, these data suggest
that lung epithelial PDIA3 plays a critical role in the maturation of IAV proteins and
propagation of the virus and illustrate the potential of utilizing host PDIs as a target for
anti-viral therapies.
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Summary:
Protein folding within the endoplasmic reticulum (ER) exists in a delicate balance;
perturbations of this balance can overload the folding capacity of the ER and disruptions
of ER homeostasis is implicated in numerous diseases. The unfolded protein response
(UPR), a complex adaptive stress response, attempts to restore normal proteostasis, in part,
through the up-regulation of various foldases and chaperone proteins including redoxactive protein disulfide isomerases (PDIs). There are currently over 20 members of the
PDI family each consisting of varying numbers of thioredoxin-like domains which,
generally, assist in oxidative folding and disulfide bond rearrangement of peptides. While
there is a large amount of redundancy in client proteins of the various PDIs, the size of the
family would indicate more nuanced roles for the individual PDIs. However, the role of
individual PDIs in disease pathogenesis remains uncertain. The following review briefly
discusses recent findings of ER stress, the UPR, and the role of individual PDIs in various
respiratory disease states.
Keywords: ER stress, UPR, PDI, Disulfide Bond, pulmonary disease
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Introduction
The endoplasmic reticulum (ER) is a highly specialized organelle that plays
numerous roles in the cell. It is the primary site of the synthesis of membrane-bound and
secreted proteins, and as such maintains an oxidizing redox environment to facilitate the
formation of disulfide bonds required for the stabilization of peptide structure[1].
Additionally, numerous posttranslational modifications such as N-inked glycosylation
occur solely within the ER[2]. Approximately one-third of all proteins that traffic through
the ER contain disulfide bonds and the ER contains a vast array of chaperones and foldases
to assist in the folding of newly synthesized peptides[1, 3]. Properly folded proteins are
essential for the normal function of the cell, and potentially misfolded proteins are rapidly
degraded by the ER-associated degradation (ERAD)[4]. Under basal conditions,
approximately thirty percent of newly synthesized peptides are targeted for degradation[5].

Protein folding within the ER exists in a delicate balance, and the physiological
states of increased protein synthesis can quickly overload the folding capacity of the ER
leading to a buildup of unfolded or misfolded peptides in the ER lumen, termed ER stress.
In an effort to combat this stress the cell activates the unfolded protein response (UPR), a
highly conserved, multifaceted stress response aimed at restoring normal ER
homeostasis[6]. Collectively the UPR attenuates normal protein synthesis, upregulates
ERAD machinery, increases the size of the ER, and upregulates various chaperones,
including protein disulfide isomerases (PDIs) a large family of proteins that assists in the
oxidative folding of nascent peptides[6]. Failure of the UPR to restore normal ER
homeostasis leads to cell death through the activation of apoptotic pathways[6].
3

ER stress and activation of the UPR are common in the progression of numerous
diseases including various cancers[7], neurodegenerative disorders[8], and viral
infections[9]. The individual etiology of these disorders is as diverse as the cell’s response
to each. And the exact intricacies of the molecular mechanisms underlying activation of
the UPR and subsequent up-regulation of distinct PDIs remains poorly understood. A
greater understanding of host pathways involved could potentially aid in the development
of future treatments. The following review briefly discusses recent findings of ER stress,
the UPR, and the role of individual PDIs in various respiratory disease states.

The Unfolded Protein Response
The unfolded protein response (UPR) is a highly conserved collection of pathways
responsible for monitoring the status of the ER. In mammals the UPR consists of three
pathways each controlled by a particular sensor, inositol-requiring protein 1 (IRE1), protein
kinase RNA (PKR)-like ER kinase (PERK), and activating transcription factor-6 (ATF6)
(Figure 1). IRE1 exists in two isoforms a and b, this review focuses on solely IRE1 a, as
the role the b isoform in activation of the UPR and induction of PDIs during pulmonary
disease is less well characterized. These three pathways work in concert to decrease the
protein load of the ER while simultaneously increasing its folding capacity. If the ER stress
is too pronounced, or prolonged, the UPR directs the cell towards apoptosis[10-12].

Generally, the PERK pathway limits protein synthesis, the IRE1 pathway
increases mRNA and protein degradation and the size of the ER, while the ATF6 pathway
4

up-regulates chaperone proteins and protein degradation[10]. Each of these transducers are
integral membrane proteins residing in the ER membrane. Under normal conditions are
held in inactive conformations by GRP78, an ER resident chaperone. Under conditions of
ER stress unfolded or misfolded protein builds up within the ER lumen, GRP78 dissociates
from the sensors owing to higher affinity to exposed hydrophobic residues on the unfolded
proteins[11]. While GRP78 is considered a master regulator of the UPR, the ER chaperone
HSP47 has recently been shown as a selective regulator of the IRE1 arm of the UPR,
displacing GRP78 and facilitating IRE1 oligomerization[13]. Additionally, there is
evidence that the individual transducers can bind unfolded protein directly[14].

Following GRP78 disassociation IRE1 dimerizes and undergoes transautophosphorylation of cytosolic kinase domains[11].

Upon phosphorylation IRE1

displays endonucleolytic activity specifically targeting X-box binding protein 1 (XBP1)
mRNA, this activity removes an intron and ultimately induces a frame shift by removing a
stop codon. The spliced XBP1 (XBP1s) is translated and acts as a transcription factor
driving the expression of ER chaperones, ERAD proteins, and lipid synthesis[15]. In
mammals both spliced and un-spliced (XBP1u) are translated, interestingly while XBP1s
acts a potent transcriptional activator of UPR effector genes, XBP1u acts as a repressor of
the UPR[16] (Figure 1).

Tumor necrosis factor associated factor 2 (TRAF2) is known to interact with IRE1
under conditions of extended ER stress leading to activation of downstream inflammatory
and apoptotic signaling[10].
5

IRE1 is also capable of forming higher order structures that utilize their
endonucleolytic activity to degrade ER-localized mRNAs in a process called regulated
IRE1 dependent degradation of mRNA (RIDD)[17].

Like IRE1, PERK also undergoes dimerization and transphosphorylation
following release from GRP78. PERK then phosphorylates eukaryotic initiation factor 2a
(eIF2a) attenuating cap dependent protein translation. This decrease in global translation
leads to the cap independent translation of activating transcription factor 4 (ATF4). ATF4
leads to the expression of amino-acid transporters, genes important in protecting the cell
against oxidative stress, and XBP1[10]. ATF4 also leads to the expression of C/EBP
homologous protein (CHOP), another transcription factor that drives the cell towards
apoptosis[10].

Unlike both IRE1 and PERK, ATF6 can exist as either a monomer or an oligomer,
stabilized by disulfide bonds, while still bound to GRP78. ATF6 contains a Golgi
localization signal that is masked by GRP78, upon disassociation ATF6 is translocated to
the Golgi body where it is consecutively cleaved by two proteases SP1 and SP2[18].
Interactions with PDIs ensure that only reduced monomeric ATF6 is moved to the Golgi.
The proteases liberate the N-terminal cytosolic domain of ATF6 (ATF6-N). ATF6-N is a
transcription factor that moves to the nucleus and induces expression of various UPR target
genes. Chaperone proteins are the primary targets of ATF6-N, including GRP78, GRP94,
and PDIs[10].
6

While it is useful to separate UPR signaling pathways into discrete units, there
exists a large amount of crosstalk between them. Genes under the control of the UPR often
contain ER stress response elements (ERSEs) in their promoter regions that are responsible
for transcriptional induction. Both XBP1s and ATF6-N can bind to these elements, though
ATF6-N binding requires additional transcription factors[19]. Interestingly, XBP1s and
ATF6-N can form heterodimers, which further complicates signaling[20]. Moreover, all
three UPR pathways often involve the same proteins[10]. The PERK and ATF6 pathways
lead to XBP1 expression, which is then processed by IRE1. And all three pathways
converge on NF-κB activation, though each uses a distinct mechanism.

However, this does not mean the UPR exists in a binary state of either active or
inactive. The individual pathways of the UPR can be activated independently of one
another. For instance, numerous groups have shown differential pathway activation
following influenza infection, suggesting distinct triggers for each signaling pathway[21,
22].

Furthermore, while UPR activation is classically thought to involve the
accumulation of unfolded protein within the ER lumen, there are numerous studies
demonstrating activation of the UPR in the absence of unfolded protein. Toll-like receptor
(TLR)2 and 4 have been shown to activate IRE1 and subsequent XBP1 maturation in
macrophages[23]. Notably this XBP1 activation did not induce expression of canonical
ER stress genes, but was required for the continued production of proinflammatory
7

cytokines[23]. Similarly, it has been reported dendritic cells constitutively activate the
IRE1 arm of the UPR in the absence of ER stress, and this activation was required for
homeostasis of CD8a+ dendritic cells[24, 25]. Additionally, mitochondrial reactive oxygen
species have been shown to exacerbate TLR induced activation of the UPR[26]. These
findings are particularly interesting as the utilization of TLRs as an alternative activation
pathway would suggest that pathogens themselves or pattern-associated molecular patterns
(PAMPs)[27] and damage-associated molecular patterns (DAMPs) are directly capable of
activating the UPR[28].

Protein Disulfide Isomerases
The UPR upregulates a wide variety of chaperone proteins in an effort to restore
normal proteostasis, among these are protein disulfide isomerases (PDIs) a large family of
redox active chaperones that play important roles in the formation, reduction, and
isomerization of disulfide bonds[29]. Currently there are over 20 members of the PDI
family, each differentiated from one another by the number and organization of TRX
domains[29, 30]. Individual TRX domains are classified as catalytically active (a) or
protein binding (b) by the presence or absence of a largely conserved CXXC sequence.
(Table 1). The CXXC motif allows for the oxidoreductase activity of PDIs by alternating
between an oxidized form, where both cysteines are linked through a disulfide bond, and a
reduced form containing two free sulfhydryl groups. This effectively transfers a disulfide
to the client protein. While the individual catalytic sequences vary the overall mechanism
remains the same, with the intervening residues modulating the pKa of the reactive
residues. The N terminal Cys exists as a thiolate (-S-) anion due to its lower pKa, which
8

mediates nucleophilic attack forming a mixed disulfide. The C terminal Cys is partially
buried within the protein elevating its pKa relative to other thiols and preventing the reverse
reaction from occurring. The pKa of this C terminal Cys is rapidly decreased by a
conformational change in the protein itself, which brings the side chain of a highly
conserved arginine in close proximity to the active site. This shift in pKa changes the C
terminal Cys from a thiol to a thiolate anion, which acts to resolve the mixed disulfide
through a subsequent nucleophilic attack. Additionally, salt bridges located beneath the
active site also serve to modulate the pKa of the Cys residues. PDIs in the reduced dithiol
state participate in isomerization reactions, shuffling disulfide bonds between Cys residues,
whereas oxidized (-S-S-) PDIs introduce disulfide bonds into associated peptides. The
introduction of a disulfide bond into the client protein leaves the oxidized PDI in the
reduced state where it can be rapidly re-oxidized by an intricate network of enzymes.
(Figure 2) The isomerization of disulfide bonds does not involve a net change in disulfides,
so the enzyme remains in the reduced state following the reaction. The above process is
extensively reviewed in the following references[31, 32].

The re-oxidation of PDIs falls primarily to ERO1, which using FAD as a cofactor,
transfers electrons from PDIs to molecular oxygen reducing it to hydrogen peroxide[33].
Additional enzymes can oxidize PDIs: such as GPx7 and GPx8, two peroxidases that
directly oxidize PDIs while reducing hydrogen peroxide[34]. Glutathione is the primary
redox buffer in the ER, and reduced glutathione is known to oxidize PDI in vitro[35].
Interestingly oxidized glutathione has been shown to reduce PDIA3 in vivo, demonstrating
its buffering role. The ability to reduce PDIA3 suggests glutathione possesses the ability
9

to reduce other PDIs in vivo as well[36]. While the non-catalytic b domains lack an active
site, they nonetheless assist in the chaperone activity of PDIs by assisting in protein
binding.

PDIs were originally characterized as ER resident proteins; most members of the
family contain either a canonical KDEL sequence or a non-canonical retention sequence.
Despite the near total presence of an ER retention sequence PDIs are commonly found
throughout the cell, at the cell surface, or even preferentially secreted from the cell[37].
The dispersal throughout the cell despite the presence of a retention sequence may suggest
unexplored roles for non-canonical retention sequences.

As one might expect, owing to the high degree of homology in the PDI family
there exists a large amount of redundancy in terms of both functionality and client proteins.
However, certain proteins appear to be clients of specific PDIs[38]. PDIA3 has enhanced
specificity towards glycoproteins owing to its association with both calreticulin and
calnexin, two lectin-based chaperones within the ER lumen[39].
UPR and PDIs in asthma and pulmonary fibrosis
The UPR is initiated to manage the ER stress, but intense ER stress can result in
apoptosis. Excessive ER stress and unhindered UPR can lead to apoptosis,
proinflammatory signaling, and epithelial-mesenchymal transition (EMT), features that
have all been linked to lung fibrosis[40-43] and asthma [39, 44-46].
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Although, evidence is emerging, that downstream of UPR, PDIs are upregulated
in both asthma and pulmonary fibrosis, their function in the pathophysiology of lung
diseases is not well understood. We have identified that various PDIs are upregulated in
allergic asthma [39, 45], and their increases correlated with the higher bronchodilator
response or blood eosinophilic counts in allergic asthmatics [39, 45]. Intriguingly our indepth analysis of lung epithelial specific knockouts of PDIA3 demonstrated that PDIA3
specifically regulate, eosinophilic, and pro-fibrotic responses in lung epithelial cells by
oxidizing cysteine sulfhydryl (-SH) groups in Eotaxin, Periostin, and EGF[45].
Furthermore, we also demonstrated that PDIA3 facilitates -S-S- mediated oligomerization
of pro-apoptotic BAK to induce intrinsic apoptosis in allergic airway disease models[45,
46]. Ablation of Pdia3 specifically in lung epithelial cells attenuated, apoptotic,
inflammatory, and fibrotic responses in a model of allergic airway disease[45]. These and
other literature have led to the hypothesis that heterogeneous severe asthma could
potentially be classified as an endotype of asthma[47].

Although, there is very little known about the impact of PDIs in pulmonary
fibrosis recent literature have highlighted that PDIs potentially regulate disulfide bonds in
many pro-apoptotic and pro-fibrotic proteins including collagen crosslinking enzyme lysyl
oxidase like 2 (LOXL2)[45, 46, 48]. Literature have also indicated that PDIA3 drives the
trans-differentiation of murine alveolar epithelial cells and it is regulated by pro-fibrotic
injury in mice[49]. We have also identified that PDIA3 as a regulator of -S-S- bonds in
death receptor CD95 (FAS) and inhibition or downregulation of PDIA3 decreases -S-S-

11

bonds in FAS, lung epithelial apoptosis and ultimately attenuation of pulmonary fibrosis
in murine models of pulmonary fibrosis[46].

So far there are no proven therapeutics available to inhibit PDIs in the clinic,
however, decades of research from various laboratories have identified many inhibitors
that have shown in-vivo and in-vitro efficacy in inhibiting PDIs. Interestingly, rutinosides
(plant flavonoids) that are known to inhibit PDIs are now being used in different clinical
studies [50], also it is interesting to note that Dr. Stockwell’s group have identified LOC14
as a specific inhibitor of PDIA1 and –A3[51, 52]. This literature suggests that UPR and
subsequent induction of PDIs regulate pathology of various diseases and inhibiting PDIs
may be a potential therapeutic approach that would benefit patients with chronic diseases.
UPR and PDIs in respiratory viral infection
Approximately 40 viruses are known to interact with the UPR, with many of these
ultimately causing the induction of ER chaperone proteins[53]. In this section we highlight
a few common respiratory viruses that display significant morbidity and mortality while
also being known to cause exacerbations of lung diseases, with a specific focus on
influenza[54].
Influenza
There are four types of influenza virus: A, B, C, and D; all are segmented RNA
viruses and similar in composition and structure[55-58]. Of these four types A and B are
the most clinically relevant[55, 59], with each being capable of causing seasonal epidemics,
while A is responsible for recurrent pandemics, most recently in 2009, and are associated
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with significantly enhanced morbidity and mortality[60]. Influenza C is capable of
infecting humans but causes extremely mild to asymptomatic infections[61].

Influenza A virus (IAV) circulates in a wide range of mammalian and avian hosts,
and it is this wade host range along with the segmented genome that is responsible for the
pandemic potential of the virus[55, 59]. The segmented genome allows for reassortment
or exchange of genetic information during mixed infection of cells with different
viruses[62], resulting in rapid unpredictable change to the proteins of the virion, termed
antigenic shift.

This is contrast to subtle changes brought about through errors in

replication, termed antigenic drift[63]. While all strains of the virus can reassort the limited
host range of B, C, and D prevents an extreme phenotypic change[60, 64, 65]. Influenza
B and C primarily infect humans, though B can infect seals as well[66, 67]. Influenza D
infects ruminants and are not known to cause disease in humans[56]. While antigenic shift
can affect any viral protein, its effect is arguably most significant when it occurs on the
viral surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) the two major
antigenic determinants of the virus[68].
Influenza hemagglutinin
HA is largely responsible for viral binding and entry into the target cell, generally
interacting with sialic acid residues on host proteins[69]. This interaction allows for
clatherin mediated endocytosis ultimately leading to fusion of the viral and cellular
membranes depositing the viral core in the cytoplasm of the cell[70]. HA is synthesized
Into the ER as a roughly 70kD monomer (HA0), this monomer undergoes processing
within the ER to remove an N terminal signal sequence as well as oxidative folding
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utilizing host redox active chaperone proteins[38, 39]. Once fully processed the HA
monomers noncovalently oligomerize into a homotrimer and are sent to the Golgi body[71,
72]. In the Golgi gylcosyl groups are added and modified and the processed trimer is sent
to the plasma membrane where it aids in viral budding[39]. HA0 is inactive and requires
cleavage by host proteases to become active[73]. This cleavage results in two fragments,
50kD HA1 which contains the globular head region of the protein responsible for binding
to the target cell, and 20kD HA2 which contains the fusion peptide[69, 71]. HA1 and 2
are linked by disulfide bonds that help stabilize the unstable structure of the cleaved
HA[59]. Regardless of the viral strain cleavage occurs after oligomerization[39].

Through the entry process HA is principally responsible for setting the host range
and tissue tropism of the individual influenza strains[72]. IAV HA is currently has into 18
subtypes divided into two antigenically distinct groups[68, 74]. H1, 2, 5, 6, 8, 9, 11, 12,
13, 16, 17, and 18 comprise group 1 and H3, 4, 7, 10, 14, and 15 comprise group 2[55, 75,
76]. H17 and 18 have been recently isolated from bats and bind to MHCII receptors on
target cells, which may have interesting and profound implications on the immune response
and overall pathogenesis of these viruses[77]. Despite the rather low overall sequence
homology between HA groups, roughly 40%, they share key important amino acid residues
responsible for substrate binding and membrane fusion as well as overall structural
homology[59, 76]. Nearly all HA subtypes can be isolated from waterfowl where influenza
typically presents as an asymptomatic gut infection[78]. H1, 2, and 3 are the main subtypes
circulating in humans[59]. Avian viruses typically bind to a2,3 linked sialic acid residues,
while human viruses tend to bind to a2,6 linked residues[60]. Porcine viruses bind to both
14

types of linkages, these specificities are believed to reflect the abundance of these different
linkages on tissues at different sites of infection, lung epithelial cells form human viruses
and intestinal epithelial cells for avian viruses[60]. Swine lung epithelial cells contain both
types of linkages and may explain why swine are viewed as the primary generators of
pandemic influenza strains[55, 79]. Interaction with sialic acid residues are not the only
factor involved in determining host range, the cleavage and stability of HA also play
important roles[72].

The HA trimer is anchored to the surface of the virion and extends roughly 14 nm
from the surface[59, 80]. The cleavage site is in a loop located towards the bottom of the
trimer close to the interface with the viral membrane, typically comprised of a single
arginine residue, termed a monobasic site[75]. H5 and H7 have the potential for significant
modifications to this loop, adding additional basic amino acids, known as a polybasic site,
as well as insertions of other amino acids[81]. These supplementary residues alter the
cleavage specificity of HA and extend the loop easing interaction with proteases[59, 82].
HAs containing a monobasic site are typically cleaved by tissue specific proteases at the
plasma membrane of the cell or after the virus has left the cell[83], while HAs containing
a polybasic site can be cleaved by more ubiquitously expressed proteases like trypsin or
plasmenogin, and can be cleaved inside the cell before viral budding[72, 84]. These
changes can lead to a virus that results in fatal disease in birds and are called highly
pathogenic avian influenza (HPAI) viruses[85]. These highly pathogenic viruses are
distinct from pandemic strains and are potentially capable of jumping from birds directly
to humans with no reassortment[59, 86]. These modifications of HA are also associated
15

with drastic alterations in overall stability of the trimer.

Upon acidification of the

endosome cleaved HA undergoes an irreversible conformational change exposing the
fusion peptide, if this change occurs prematurely it can have profound effects on viral
fusion and infection[80]. HAs containing a monobasic site are typically more stable being
activated around pH 5, while ones containing polybasic sites can be activated at pH 6[75].
This is the pH of the upper respiratory track and nasal passages in humans[87] and may
explain the capacity of HPAI for jumping directly to humans.

While HA is largely responsible for the host range and tropism it is important to
remember that these are ultimately polygenic effects, for instance the pandemics of 1957
and 1968 had changes to their polymerase subunits and these changes have been
demonstrated to modulate host range[88].

Despite the importance of HA, it is largely ignored as a therapeutic target, while
it is an important antigenic determinant of the virus and as such will likely be a target of
the immune system, there are no FDA approved compounds targeting HA[89]. Umifenovir
is commonly used to treat IAV infection in both Russia and China, it is believed to prevent
association between sialic acid residues and HA, blocking viral fusion[90]. Umifenovir
also possesses some immunomodulatory effects, however given its primary target it is
likely most effective when given during the first 48 hours of infection during peak viral
replication[90, 91]. While not currently FDA approved in the US, there are currently a
number of clinical trials being conducted in other countries, not only against influenza
infection but also novel coronavirus infection as well.
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Influenza neuraminidase
NA is the other major surface glycoprotein of the virion, accounting for up to 20%
of the glycoproteins on the surface[92]. There are currently 11 NA subtypes, like HA it
divided into two antigenically distinct groups[77]. Group 1 contains N1, 4, 5, and 8, while
group 2 contains N2, 3, 6, 7, and 9[60, 77]. N10 and 11 are classified as NA like homologs
and do not belong to either group and do not possess typical NA activity[77]. NA has exosialidase activity, cleaving terminal sialic acid residues, and plays a critical role in viral
exit, preventing viral aggregation on the host cell[55, 60, 75]. Additionally, this sialidase
activity plays a minor role in viral entry, cleaving sialic acid residues in mucus lining the
epithelial cells of the airway[93].

NA maturation occurs much like HA, both are

synthesized into the ER, require extensive oxidative folding through interaction with host
redox active chaperone proteins, and undergo further processing in the Golgi before being
transported to the plasma membrane[60, 94]. However, unlike HA, NA does not need to
be cleaved in order to be active. While both HA and NA oligomerize, active NA is a
homotetramer, and the individual monomers are held together by intermonomer disulfide
bonds[94]. Previous work has demonstrated these bonds are required for NA activity[95].
Interestingly the stalk domain of NA can be variable in length resulting in an NA tetramer
that can be either slightly above or slightly below HA trimer, this has implications for the
replication and pathogenesis of the virus[96, 97].

Given NAs importance it is not surprising that it is a common target for antiviral
therapies, NA inhibitors are currently one of three classes of FDA approved anti influenza
drugs[89, 98].

Despite the difference between the NA groups the active sites are
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remarkable similar showing a high degree of conservation among amino acids[75].
Though antigenic drift often rapidly decreases the effectiveness of these inhibitors. A
single amino acid substitution H274Y is enough to significantly decrease the effectiveness
of oseltamivir though it has comparatively little effect of the related compound
zanamivir[99]. These oseltamivir resistant strains of IAV comprised the majority of
influenza isolates 2007-2008 influenza season[100].

Despite being utilized mainly for viral egress NA may have additional strain
specific functions. The WSN strain HA is cleaved by the enzyme plasminogen[101], this
in and of itself is not unusual, however, researchers have found that the plasminogen is
actively recruited by the WSN NA[102]. Thus, in addition to cleaving sialic acid residues
the WSN NA concentrates plasminogen in an area where it is able to be utilized by the
virus, either at the cell surface or after the virus has released.

Influenza A virus (IAV) is known to activate different arms of the UPR depending
on the model[21, 22, 103].

Hassan et al. demonstrated in isolated primary human

tracheobronchial epithelial (HTBE) cells that IAV infection activated the IRE1 branch of
the UPR but not the PERK or ATF6 branches[21]. That same year Roberson et al. showed
in isolated primary mouse tracheal epithelial cells IAV infection strongly activated the
ATF6 branch, but not PERK or IRE1[22]. As indicated the models for these two studies
are different which may account for the differences in UPR activation. However, one less
explored difference between the two studies is the time post viral infection in which the
activation status of the UPR was explored. Hassan et al. examined UPR activation shortly
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after infection while Roberson et al. explored UPR activation at 24- and 48-hours post
infection. This distinction may help explain the contradictory results as the two studies are
examining the UPR at different points of the viral replication cycle where reproductive
needs and thus utilization of host proteins may be quite different. A recent third study by
Landeras-Bueno et al. using chemical genomics showed IAV infection leads to the
attenuation of the PERK branch of the UPR in A549 cells[103]. Interestingly, in contrast
to the previous studies they showed no down regulation of IRE1 or ATF6. Again, this may
be due to differences in the time points examined.

The relationship between IAV and PDIs is more straightforward, in 2006 Solda et
al. clearly demonstrated PDIA3 was required for efficient folding of IAV HA in vitro[38].
They also showed while other PDIs were able to act as surrogate chaperones for various
proteins, efficient HA disulfide bond formation required PDIA3. Loss of IAV replication
in cells treated with siRNA against PDIA3 supported this finding, though direct results on
viral proteins were not examined[22]. More recently expanded siRNA screens identified
PDIA1 and 4 in addition to PDIA3 as having a role in IAV replication[104]. The authors
found substantial decreases in both IAV NP and M1 protein levels as well as significant
decreases in viral transcript levels following siRNA treatment. Both M1 and NP lack
disulfide bonds as part of their functional conformations[105], thus it is unclear whether
the examined PDIs are interacting directly with the NP or M1.

Building on those results we have shown PDIA3 plays an important role in IAV
replication in vivo. Utilizing conditional PDIA3 knockout mice we demonstrate PDIA3
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deletion in lung epithelial cells significantly decreases levels of viral transcripts and
proteins, as well as corresponding decreases in inflammatory cytokines and inflammatory
and immune cells in the bronchoalveolar lavage fluid (BALF)[39]. Moreover, we show
ablation of Pdia3 in the lung epithelium diminishes IAV mediated methacholine induced
AHR, providing a physiological readout illustrating the importance of PDIA3 in IAV
replication[39].

Other common respiratory viruses
Rhinovirus (RV) has recently been shown to cause impaired UPR activation in
primary Cystic Fibrosis (CF) bronchial cells[106]. However, this impairment of UPR
activation does not appear to be cell intrinsic as activation with known chemical inducers
of the UPR produces a robust UPR response as indicated by increased GRP78 and CHOP
expression[106]. Moreover, chemical activation of the UPR in RV infected primary cells
significantly impeded viral replication and subsequent release of the virus. Suggesting that
like IAV, RV is capable of directly activating the UPR. This is confirmed by a recent study
from Song et al. showing the human RV16 infection, specifically the non-structural protein
2B activates both PERK and ATF6 UPR pathways in H1-HeLa cells[107]. Interestingly
this protein also simultaneously inactivates the IRE1 pathway by blocking phosphorylation
and subsequent XBP1 splicing[107].

Like the above viruses Respiratory Syncytial Virus (RSV) infection activates the
UPR. In both A549 cells and primary HTBE cells UPR activation is characterized by
increased GRP78 levels, and activation of both the IRE1 and ATF6 pathways, though no
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PERK activation was detected[108]. However, a study involving a mouse model exploring
RSV’s role in lung fibrosis found PERK activation 7 days post infection along with
elevated ATF6, GRP78[109]. XBP1 levels were not elevated and IRE1 activation was not
explored. Intriguingly, while RSV activates the IRE1 branch of the UPR in both cell lines
and isolated primary cells, IRE1 inhibits RSV replication[108]. In both Ire1-/- mouse
embryonic fibroblasts and A549 cells treated with an IRE1 inhibitor viral transcript and
protein levels were significantly higher than in RSV infected control cells[108]. Though
the exact mechanism for this is unclear, it may be related to IRE1 RIDD endonuclease
activity.

Coronaviruses (CoV) are another virus family capable of causing respiratory
exacerbation as well as significant illness on their own[110]. SARS-CoV and MERS-CoV
in particular have high pandemic potential and are associated with significant
mortality[110]. It is well established CoV can induce the UPR in culture, this UPR
activation has been linked to the spike (S) protein and for certain CoV the exact amino acid
domain responsible is known[111, 112]. The S protein of SARS-CoV and CoV-HKU1,
both beta-coronaviruses, induce the transcription of GRP78, GRP94, and CHOP through
activation of the PERK pathway in vitro[111]. Cells infected with MHV-A59, a model
murine CoV in the same family as SARS and MERS, show activation of all three UPR
branches, though ATF6 activation is limited later in infection[110]. Relative activation of
UPR branches varies between individual CoV as cells infected with SARS-CoV show
limited XBP1 slicing and ATF6 cleavage[113, 114]. Interestingly, an in vitro study using
a selective PERK inhibitor found alleviating translational repression increased the levels
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of viral proteins but decreased viral titers[110]. This was hypothesized to be due to
increased translation of host anti-viral proteins.

There is currently little information on the relationship between RV, RSV, and
CoV and host PDIs. Thus, any potential interactions remain to be characterized, and any
prospective anti-viral pharmacological influence need to be explored.

While we have limited ourselves to a discussion of respiratory viruses known to
interact with the UPR, there are numerous other non-respiratory viruses that do so[53].
Herpes Simplex Virus[115], Dengue Virus[116], Hepatitis B[117], as well as HIV[118] all
interact with the UPR or PDIs despite all infecting drastically different cell types. These
host-viral interactions may provide promising targets for the basis of the development of
future antivirals
UPR and PDIs in immune signaling
Both the UPR and PDIs play important roles in immune signaling and activation.
Increased expression of proinflammatory cytokines during ER stress has been firmly
established[119]. And because it allows for ER expansion, increased protein production,
and subsequent protein secretion, activation of the UPR is needed for the development and
function of both secretory and immune cells[15, 120, 121]. Additionally, GRP94 has been
shown to be involved in the maturation of Toll-like receptors[122].

PDIA3 is a core component of the peptide loading complex, required for antigen
presentation through MHC class I[123]. In addition, PDIs play important roles in cytokine
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folding and maturation. siRNA knockdown of PDIA3 in the lung epithelium has been
shown to alter the oxidative folding of eotaxin and periostin in mice[45]. PDIA1 is found
at high levels in the secretory granules of eosinophils, suggesting a direct role in cytokine
secretion[124].
UPR and PDIs in feedback regulation
There are an increasing number of papers exploring the redox regulation of the
UPR sensors through thiol-disulfide exchange[125]. In other words, modulation of the
UPR itself through its downstream PDI effectors. A recent study determined PDIA1 and
A3 are important in the regulation of PERK, utilizing lentiviral PDIA3 depletion in
combination with small molecule based PDI inhibition the authors concluded oxidized
PDIA1 was an important activator of PERK, while PDIA3 was critical to regulating the
oxidation state of PDIA1[125].

One group found PDIA6 is important in modulating IRE1 signaling through
interaction with Cys148 of the activated protein, facilitating its decay, thus acting as an
attenuator of IRE1 signaling[126]. Another study by the same group exploring the UPR
and glucose stimulated insulin secretion found PDIA6 regulates the RIDD activity of
IRE1[127]. Utilizing shRNA against PDIA6, Eletto et al. found that during UPR activation
through chemical stressors, PDIA6 modulates the kinase activity of PERK as well as the
XBP1 splicing ability of IRE1. However, upon activation due to glucose concentration
only RIDD activity of IRE1 is triggered, PDIA6 regulates this activity, and that this
regulation was dependent of the enzymatic activity of PDIA6, rather than expression of
PDIA6[127].
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Another different study found PDIA5 is important for ATF6 activation and export
during ER stress[128]. Higa et al. determined this activation was redox dependent and
PDIA5 was involved in disulfide bond rearrangement of ATF6 which facilitated its
transport to the Golgi[128]. A very recent study utilizing trap mutants of various PDIs
found PDIA16 modulates trafficking of ATF6 to the Golgi and assists in proteolytic
cleavage[129].

Another study using shRNA depletion of PDIs found PDIA4 regulates

ATF6 activity, as increased GRP78 expression was detected specifically following PDIA4
deletion as opposed to other PDIs[130]. Though, the exact nature of this control was not
explored.

This avenue of research is promising as it demonstrates the possibility of
controlling aberrant or exuberant UPR activation, or modulating specific arms of the UPR,
through inhibition of individual PDIs.
Small molecule inhibition of PDIs
Given the scope of PDIs it is not surprising there is plentiful investigation into
modulating their activity. Numerous chemicals have been shown to inhibit PDI activity,
from antibodies[131] and hormones[132], to antibiotics[133]. In the past few years there
has been an influx of inhibitors identified from small molecule screen libraries with
increasing specificity towards PDIs[134-139]. Most of these molecules are identified as
potential chemotherapeutic agents and have been characterized against PDIA1, the
prototypical member of the PDI family[140]. However, given the high degree of homology
between PDI family members some inhibitory activity against other PDIs is often
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predicted. A full description of currently available small molecule PDI inhibitors can be
found in Table 2, the following section will highlight a few key inhibitors.
16F16 was the first of this new wave of inhibitors, it acts by covalently binding to reactive
Cys residues in the active site of PDIs[52]. Hoffstrom et al. utilized it to explore
mechanisms linking PDIs to apoptotic cell death[52]. E64FC26 is a novel PDI inhibitor
based off of an indene moiety that acts as a pan inhibitor of numerous PDIs though the
inhibitory mechanism in unclear[141]. The authors found E64FC26 improved survival in
a mouse model of multiple myeloma, with little adverse effects. KSC-34 is a particularly
interesting inhibitor, it displays enhanced specificity towards PDIA1, which is not unusual,
but KSC-34 is selective towards the N-terminal CGHC active site of the protein[140]. This
means KSC-34 can be used to explore specific functionalities and protein interactions of
each individual active site. Additionally, the specificity of this inhibitor is encouraging in
that is suggests the possibility of identifying novel inhibitors with the same level of
specificity targeted towards other PDIs.

LOC14 is unique, it is a reversible PDI inhibitor that binds adjacent to the CGHC
active site and locks the enzyme in an oxidized conformation, though the exact residues
remain to be elucidated[51]. LOC14 has been found to be neuroprotective in both cell
culture and animal models and displays high stability[51]. We have recently demonstrated
LOC14 is also capable of inhibiting PDIA3 as well as PDIA1, and that treatment with
LOC14 significantly decreased Influenza replication and the maturation of viral
proteins[39]. Another group has demonstrated the redox modulating effects of flavonoid
compounds on PDIA3[142]. Rather than directly interacting with the active site these
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compounds bind to residues on the protein binding b and b’ domain absent on other PDIs
[142, 143]. These flavonoids are interesting as they may provide a structural basis for the
design of specific PDIA3 inhibitors.

The above compounds represent an expansive range of mechanisms and targets
within the PDI family, from E64FC26 acting as a pan PDI inhibitor[141], to KSC-34 acting
toward a specific active site on PDIA1[140]. PDIs are being found to play increasingly
important roles in a wide variety of conditions and cellular activities, though current
techniques to elucidate their exact role remain limited. Conventional RNA interference
techniques take time to ensure sufficient knockdown of a target gene and targeting multiple
genes simultaneously can pose additional problems. Employing targeted inhibitors allows
for rapid decreases in protein activity and could theoretically be titrated to achieve a desired
activity level. We have already demonstrated the efficacy of these inhibitors by utilizing
them to determine the role of PDIs in oxidative folding of influenza proteins[39], while
Cole et al. explored the specific role of the PDIA1 A site on protein folding and
secretion[140]. Current compounds are able to target some of the PDI family, though
inhibitory action against all PDIs has yet to be explored, and highly specific inhibitors
towards PDIs other than PDIA1 remain to be developed. Nonetheless, the development of
increasingly specific inhibitors specifically targeted towards individual PDIs would
provide an invaluable tool to determine the distinct role of unique PDIs during disease
pathogenesis.
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Conclusion
The UPR and PDIs play critical roles in numerous cellular processes. Much
remains unknown regarding their role in normal responses and their impact on the
development of disease. Investigation into the branches of the UPR and their downstream
effectors remains challenging. However, small molecule PDI inhibitors provide an exciting
opportunity to tease apart the molecular mechanisms of ER stress and provide potential
platforms for the development of future therapeutics.
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Figure Legends
Figure 1: Representation of canonical UPR signaling pathways. The UPR is activated
by a buildup of unfolded protein within the ER lumen. GRP78 dissociates from the three
ER stress sensors IRE1, ATF6, and PERK. Dimerization of IRE1 leads to
autophosphorylation activating ribonuclease activity specific to XBP1 mRNA.

This

splicing generates XBP1s which is transported to the nuclease and induces the expression
of UPR target genes. IRE1 phosphorylation also activates TRAF2 which directs the cell
towards apoptosis through JNK signaling. IRE1 is also capable of associating into higher
order structures which allow for non-specific degradation of ER associated mRNAs
(RIDD). PERK dimerization leads to autophosphorylation activating kinase activity
specific to eIF2a, halting protein translation. This loss of translation drives expression of
ATF4 which acts as a transcription factor and induces the expression of UPR target genes.
eIF2a is regenerated by GADD34. Upon dissociation of GRP78 from ATF6, ATF6 is
transported to the Golgi where it is cleaved by cellular proteases to produce a transcription
factor which induces the expression of UPR target genes.

Figure 2: Functions of PDIs in oxidative folding. A. Oxidized PDIs catalyze disulfide
bond formation of nascent peptides in the ER. Leading to proper oxidative folding or nonnative disulfide bond formation. Reduced PDIs facilitate isomerization of disulfide bonds.
B. PDIs are oxidized via interactions with ERO1. ERO1 uses FAD to transfer electrons to
molecular oxygen generating hydrogen peroxide. PRX4 can also directly oxidize PDIs.
PDIs transfer disulfides to client proteins. Glutathione contributes to disulfide bond
reduction.
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Mode of action

Competitive inhibitor, binds to free thiols in substrate binding region. Cell impermeable
Irreversibly binds to cysteine residues in active site. Cell permeable
Allosteric inhibitor. Binds adjacent to active site, forces protein to maintein oxidized
conformation. Reversible. Cell permeable
Irreversibly binds to cysteine residues in active site. Cell permeable
Allosteric inhibitor. irreversibly binds to conserved lysine directly adjacent to the active site.
Cell permeable
Irreversibly binds to cysteine residues in active site. Cell permeable
Pan-PDI inhibitor, mechanism unknown. cell permeable
PDIA1 inhibitor, selective for C53 in a doain active site. Cell permeable
PDIA1 inhibitor, mechanism unknown. Reversible. Cell permeable
PDIA1 inhibitor, selective for C53 in a doain active site. Cell permeable
PDIA1 inhibitor, mechanism unknown. Cell permeable
Flavanoid compound, binds to tryptophan residues near the active site of PDIA3
Flavanoid compound, binds to tryptophan residues near the active site of PDIA3.
PDIA1 inhibitor, binds to b' domain. Reversible. Cell impermeable
Allosteric inhibitor, binds near active site. Reversible. Cell permeable
Anti-PDIA1 antibody
Binds to bb' domain
Believed to bind with cysteine residues in active site

Table 2: Characteristics of various PDI inhibitors
Compound name
Bacitracin
16F16
LOC14
PACMA31
CCF642
P1
E64FC26
KSC-34
ML359
RB-11-ca
Juniferdin
Eupatorin
Eupatorin-5-methyl ether
Quercetin-3-rutinoside
T8
RL90
17β-estradiol
35G8
* Clinicaltrial.gov

Yes (57)
No

Clinical Trial *

86

39,51

85
52

Reference

7

No

No

87
93
92
88
89
88
94,95
94,95
50
90
83
84
91

No

No
No
No
No
No
No
No
No
No
No
No
Yes (2054)
No
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ABSTRACT
Protein disulfide isomerases (PDI) are a family of redox chaperones that catalyze
formation or isomerization of disulfide bonds in proteins. Previous studies have shown
that one member, PDIA3, interacts with influenza A virus (IAV) hemagglutinin (HA), and
this interaction is required for efficient oxidative folding of HA in vitro. However, it is
unknown whether these host-viral protein interactions occur during active infection and
whether such interactions represent a putative target for the treatment of influenza
infection. Here we show that PDIA3 is specifically upregulated in IAV-infected mouse or
human lung epithelial cells and PDIA3 directly interacts with IAV-HA. Treatment with a
PDI inhibitor, LOC14 inhibited PDIA3 activity in lung epithelial cells, decreased
intramolecular disulfide bonds and subsequent oligomerization (maturation) of HA in both
H1N1 (A/PR8/34) and H3N2 (X31, A/Aichi/68) infected lung epithelial cells. This reduced
disulfide bond formation significantly decreased viral burden, and also pro-inflammatory
responses from lung epithelial cells. Lung epithelial-specific deletion of PDIA3 in mice
resulted in a significant decrease in viral burden and lung inflammatory-immune markers
upon IAV infection, as well as significantly improved airway mechanics. Taken together,
these results indicate that PDIA3 is required for effective influenza pathogenesis in vivo,
and pharmacological inhibition of PDIs represents a promising new anti-influenza
therapeutic strategy during pandemic and severe influenza seasons.
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AUTHOR SUMMARY
Current Influenza virus therapies target viral proteins and are limited in their
effectiveness owing to rapid viral mutation. Understanding host cellular and molecular
processes utilized by the virus during its replication may aid in the development of new
therapeutic interventions to improve patient survival. Influenza proteins such as
hemagglutinin (HA) rely on disulfide bonds for stability and activity and as such rely on
host redox enzymes of the endoplasmic reticulum (ER) and the secretory pathway to
express and assemble fully mature viral proteins. Past work has shown that one of these
enzymes, protein disulfide isomerase (PDI) A3 is important for efficient folding of HA and
viral replication in vitro. However, little is known about how PDIA3 mediates this effect
or its role during active viral infection in vivo. Here, we demonstrate that PDIA3 is required
for productive viral infection in vivo using conditional PDIA3 knockout mice. Moreover,
we also show that small molecule mediated inhibition of PDIs with the reversible inhibitor
LOC14 results in decreased viral replication, inflammation, and oxidative folding of HA.
Thus, PDIA3 and other host redox active enzymes may provide targets for future therapies,
and LOC14 may provide the basis for novel therapeutic interventions.

INTRODUCTION
Viruses harness their host cell transcriptional machinery and endoplasmic
reticulum (ER) to express and properly fold and mature virus proteins, respectively [1].
Viral proteins often rely on the redox-dependent formation of disulfide bonds (-S-S-) for
stability and function [2]. In general disulfide bonds within membrane and secretory
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proteins are constructed in the ER and require ER-localized oxidoreductases [3-5]. One of
these oxidoreductases is protein disulfide isomerase (PDI) A3, which belongs to a family
of PDIs that catalyze formation and isomerization of disulfide bonds within nascent
peptides in the ER [6, 7]. PDIA3 is unique among other PDIs in that it has an enhanced
specificity towards glycoproteins owing to its interactions with calreticulin and calnexin,
two lectin binding chaperone proteins within the ER [8]. In addition to numerous roles with
in the cell, recent studies have linked PDIA3 with various cancers and the onset of
neurodegenerative disorders [9, 10], though its role during viral infection is less well
studied.

Influenza specifically infects and replicates in lung epithelial cells due to the
presence of compatible sialic acid residues that can bind to influenza hemagglutinin (HA)
[11, 12]. Previous work has shown that influenza HA contains several disulfide bonds and
traverses through the ER to attain its final conformation via ER based folding and
glycosylation[13, 14]. PDIA3 has been shown to interact with IAV-HA and to facilitate
disulfide bond formation in HA during its passage through the ER [15]. It is also evident
that these disulfide bonds formed by PDIA3 are essential for HA activity in vitro [15-17].
Despite in vitro evidence it is not well established whether PDIA3 is required for viral
burden in vivo, nor is it known about the effect of PDIA3 deletion has on the disulfide
status and maturation of HA during active IAV infection in primary lung epithelial cells
and in mouse lungs.
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In this study, we observed that PDIA3 is specifically upregulated in IAV-infected
lung epithelial cells and mouse lungs as compared to other PDI family members.
Additionally, the newly discovered small molecule inhibitor of PDI, [18] LOC14 exhibited
the capacity to inhibit recombinant (r)PDIA3 at an IC50 of approximately 5 µM. Treatment
of IAV-infected primary mouse tracheal epithelial cells (MTECs) with LOC14 resulted in
decreased viral burden and pro-inflammatory cytokine production. IAV-HA showed a
deficiency in disulfide bonds in cells treated with LOC14. Furthermore, this deficiency of
disulfide bonds also decreased mature IAV-HA, indicating that PDI inhibition affects HA
maturation within the host cell. Following influenza infection, mice with lung epitheliumspecific knockout of Pdia3 showed decreased overall viral burden, reduced inflammation
and improved lung mechanics.

RESULTS
PDIA3 expression is increased following IAV infection
Wild type (C57BL/6NJ-WT) mice were infected with 2000 egg infectious units
(EIU) of influenza A virus (IAV) strain H1N1 (PR8) and lung lysates were analyzed for
PDI expression. Six days post infection a significant increase in Pdia3 transcripts were
observed when compared to other Pdia gene transcripts (Fig 1A). Mice infected with
replication-deficient, UV irradiated (mock) virus, did not show any increases in Pdia3,
suggesting the Pdia3 induction depends on active viral replication. We next examined
PDIA3 protein expression in the lung sections of PR8 infected WT mice, and observed a
marked increase in PDIA3 levels predominantly in the bronchial epithelial cells in mice
infected with PR8 compared to mock treated mice (Fig 1B). Next, we sought to determine
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if this increase following IAV infection was exclusive to PR8 H1N1 or also prevalent in
other influenza strains. Shoemaker et al. [19] have performed microarray using lung
homogenates of mice infected with various strains of influenza virus, to examine gene
expression over different time points. A retrospective analysis of this microarray data set
(GSE63786) revealed Pdia3 is the only Pdi significantly upregulated compared to
uninfected controls at 72 hrs, 120 hrs, and 168 hrs post infection with various strains of
IAV (Fig 1C & S1). A similar microarray experiment was performed by Gerlach et al. [20]
in human lung epithelial cells 36 hrs post infection and a retrospective analysis of this data
set (GSE48466) also revealed significantly upregulated PDIA3 in response to pandemic
influenza infection (Fig 1D). Despite increased expression of PDIA3 in response to
seasonal influenza infection, this was not found to be statistically significant (Fig 1D).

PDIA3 is known to interact with the hemagglutinin (HA) protein of IAV to
construct disulfide bonds (-S-S-) in HA of IAV [15]. We performed immunoprecipitations
(IPs) in human bronchial epithelial (HBE) cells after IAV infection. Upon analysis of the
immunoprecipitated samples by western blot, we found both increased PDIA3 expression,
as well as high levels of HA co-immunoprecipitating with PDIA3 (Fig 1E). Western blots
of whole cell lysate (WCL) showed clear increases in HA and PDIA3, and no alterations
in GAPDH were observed (Fig 1E). Next, we knocked down PDIA3 using siRNA and then
lung epithelial cells were infected with IAV or mock virus. Subsequent Western blot
analysis showed that knockdown of PDIA3 decreased levels of HA in IAV infected cells
as compared to scrambled siRNA transfected cells (Fig 1F).

These results suggest

following IAV infection PDIA3 is predominantly induced in human and mouse lung
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epithelial cells, and siRNA mediated decrease in PDIA3 expression diminish IAV-HA
production in lung epithelial cells.

PDI inhibitors decrease PDIA3 activity and influenza protein production
PDIs play important roles in the folding of cellular proteins, and the prototypical
PDI, PDIA1, has been found to be implicated in numerous diseases [21]. As such there
are several commercially available small molecule inhibitors that target PDIA1, while little
is known regarding the effect of these inhibitors on other PDIs. It is presumed that these
inhibitors will have inhibitory effect on other PDIs owing to the high conservation of a
thioredoxin-like (CXXC) active site and the high degree of homology between protein
binding domains of the various PDI family members[18, 22-24]. We therefore tested four
PDI inhibitors: 16F16, LOC14, PACMA31, and CCF 642, all extensively characterized as
inhibitors of PDIA1, for their efficacy to inhibit PDIA3.

Reduction of Dieosine-

diglutathione (DiE-GSSG) has been used as an assay to determine PDI activity [25, 26].
We first determined that DiE-GSSG could also be used as a substrate for recombinant
PDIA3 (rPDIA3) (Fig 2A). Using this assay, we found that 16F16 had minimal effect on
the activity of rPDIA3, while both PACMA31 and CCF 642 showed inhibitory effects only
at high concentrations (≥100 μM) (data not shown). However, reversible inhibitor LOC14
(Fig 2B) exhibited inhibition of rPDIA3 with an inhibitory capacity at 50% (IC50) of 4.97
μM (Fig 2C and D).

It has been previously shown that PDIA3 is required for IAV propagation [17].
We therefore next examined, if pharmacological PDI inhibition would alter IAV
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propagation. We treated primary mouse tracheal epithelial cells (MTECs) with LOC14 or
vehicle control (VC) prior to IAV infection, during infection, and post infection (Fig 2E),
to avoid excessive load of inhibitors and cytotoxicity at a given time. Examination of the
cells 24 hours post infection via flow cytometry for the presence of influenza nucleoprotein
(NP) [27] (Fig 2F), detected no NP in the mock virus infected VC or 300 µM LOC14
treated cells. IAV infected VC group showed an increase in NP and we observed a dose
dependent decrease in the NP+ cells following LOC14 treatment (Fig 2F). Using these
data, we were able to calculate an effective concentration 50% (EC50) of 9.952 μM for
LOC14 based on the percentage of NP+ cells (Fig 2G).

To determine if LOC14 treatment altered PDI activity within the cell we
monitored the reduction of DiE-GSSG by lysates from IAV-infected cells treated with
either LOC14 or vehicle control. We found LOC14 treatment (Fig 2E), with repeated doses
of 10 μM (total 30 μM), decreased PDI activity in infected MTECs compared to controls
(Fig 2H). DiE-GSSG is reported to be a substrate for PDIs [26]. Taken together these
results indicate that LOC14 inhibits the oxidoreductase activity of PDIA3 and LOC14 can
be used to block viral replication.

LOC14 treatment in primary mouse tracheal epithelial cells (MTECs) alters disulfide
(-S-S-) bonds of HA
Influenza-HA is synthesized as a 70 kDa (HA0) precursor that is cleaved in the
Golgi to yield two fragments of approximately 50 kDa (HA1) and 20 kDa (HA2) following
oligomerization [28]. To determine if LOC14 alters -S-S- of HA, we treated primary
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MTECs with LOC14 (Fig 3A). Briefly, MTECs were treated with 10 μM LOC14 prior to
IAV infection, during infection, and post IAV infection; resulting in a total of 30 μM
LOC14. Western blot (WB) analysis showed that LOC14 treatment no alterations in HA0
levels compared to vehicle treated cells in IAV-infected MTECs (Fig 3B, WCL).
However, levels of cleaved HA1 showed a significant decrease following LOC14 treatment
(Fig 3B, WCL-WB, Fig S2A). PDIA3 is unique compared to other PDIs in that it
predominantly facilitates -S-S- bonds in glycoproteins that are being processed and
traversing through the ER [29]. Therefore, we next determined whether inhibition of
PDIA3 would alter -S-S- bonds of HA. We used a biotin switch assay to assess disulfides
by blocking free cysteine sulfhydryl (-SH) groups using N-ethyl maleimide (NEM) and
reducing -S-S- bonds with DTT, and then newly revealed -SH groups are labeled with
biotin-conjugated alkylating agent (MPB) (Fig 3C). This technique reveals high labeling
of proteins with -S-S- bonds and low labeling of proteins with -SH groups. Subsequent
neutravidin pull-down and Western blot analysis showed drastic decrease in -S-S- bond
formation in IAV-HA following LOC14 treatment compared to vehicle control treated cells
infected with IAV (Fig 3D). We then examined oligomerization of HA using non-reducing
SDS-PAGE. Mature HA trimers are known to be resistant to dissociation by SDS [30, 31].
LOC14 treatment increased monomeric HA and correspondingly decreased high molecular
weight HA (150-200 kDa) as compared to vehicle treated controls (Fig 3E, right lanes, DTT). Samples reduced using DTT showed no high molecular weight HA (Fig 3E, left
lanes, +DTT). Indicating LOC14 induces defects in HA oligomerization by altering
oxidative folding of HA. Interestingly, we observed a decrease in monomeric forms of
HA0 in LOC14 treated samples compared to vehicle control samples infected with IAV
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(Fig 3E, left lanes, +DTT). Potentially suggesting that a decrease in overall HA production
following LOC14 treatment

Our analysis of IAV burden in these cells showed a decrease in IAV-PA
transcripts following LOC14 treatment, but this was not statistically significant (Fig 3F).
However, we observed a significant decrease in the number of MTECs positive for IAV
NP in LOC14 treated IAV infected cells as compared to vehicle control treated cells (Figs
3G & S2B). Next, reinfection of MTECs with supernatants isolated from earlier infected
MTECs treated with either vehicle or LOC14 showed a marked decrease in the number of
cells positive for IAV NP in LOC14 treated supernatants as compared to vehicle treated
supernatants (Figs 3H & S2C), suggesting a decreased production of infectious virus
following LOC14 treatment. Quantification of mRNAs for Ccl20, and Irf7, an important
transcriptional regulator of the type I interferon response by RT-qPCR showed a significant
decrease in transcript levels following LOC14 treatment, suggesting decreased viral burden
(Fig 3I & J).

LOC14 is known to be a potent activator of the unfolded protein response
(UPR)[23]. In order to assess cytotoxic effects of LOC14 treatment we examined UPR
activation, by monitoring ATF6 cleavage and GRP78 protein expression, two transducers
of the UPR, and caspase assays (Fig S2D & E). No significant changes in either readout
was observed, indicating LOC14 treatment had no effect on cellular stress levels of either
mock or IAV infected cells 24 hrs post infection.
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Taken together these results suggest that LOC14 alters oxidative folding of HA,
and that deficit in the formation of disulfide bonds has significant implications for
oligomerization of HA and subsequent influenza burden in MTECs.

LOC14 treatment alters oxidative folding of different HA in H3N2 serotype
Owing to remarkable conservation of cysteine residues between various strains of
influenza (Fig S3) we sought to determine if alterations in oxidative folding also affected
other hemagglutinin serotypes e.g. H3. To determine the effects of LOC14 treatment on
H3 HA, we infected MTECs with X31 which contains the HA and NA genes of
A/Aichi/1/1968 (H3N2)[32]. Primary MTECs were treated with LOC14 pre- and postinfection with X31 (Fig 3A). LOC14 treatment did not alter HA0 levels compared to
vehicle treated cells (Fig 4A, WCL-WB). However, levels of cleaved HA1 showed a
significant decrease following LOC14 treatment (Fig 4A, WCL-WB, top panel, Fig S4A).
The biotin switch assay followed by neutravidin pull-down showed considerably less
disulfide bonds in IAV-HA (H3) following LOC14 treatment (Fig 4A, neutravidin-WB,
bottom panel). We then examined oligomerization of HA using non-reducing SDS-PAGE.
LOC14 treatment decreased high molecular weight HA (150-200 kDa) as compared to
vehicle treated controls (Fig 4B, right lanes, -DTT), while samples reduced using DTT
showed no high molecular weight HA (Fig 4B, left lanes, +DTT), though no corresponding
increase in monomeric HA was observed. These results suggest that a decrease in oxidative
folding in the form of -S-S- bonds of HA leads to impaired oligomerization in H3-HA of
X31. Again, we observed a decrease in monomeric forms of HA0 in LOC14 treated
samples compared to vehicle control samples infected with IAV (Fig 4B, left lanes, +DTT).
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Potentially suggesting that a decrease in overall HA production following LOC14
treatment.

Subsequent analysis of IAV burden in these cells showed a significant decrease
in IAV-PA transcripts following LOC14 treatment (Fig 4C), and a significant decrease in
the number of MTECs positive for IAV-NP in LOC14 treated IAV infected cells as
compared to IAV infected vehicle control treated cells (Figs 4D, S4B). Next, reinfection
of MTECs with supernatants isolated from earlier infected MTECs treated with either
vehicle or LOC14 showed a marked decrease in the number of cells positive for IAV NP,
suggesting decreased production of infectious virus following LOC14 treatment (Figs 4E,
S4C). Quantification of Ccl20, and Irf7, by RT-qPCR showed a significant decrease in
transcript levels following LOC14 treatment (Fig 4F and G). Taken together these results
suggest that LOC14 decreases -S-S- bonds of H1 as well as H3 HA, and that these
variations in disulfide bonds have significant implications for oligomerization of HA and
subsequent inflammatory response independent of influenza strain.

Ablation of Pdia3 in the lung epithelium attenuates viral burden in mice
To determine whether PDIA3 in airway epithelial cells contributes to the
establishment of viral burden, lung inflammation and airway mechanics, we generated a
doxycycline inducible transgenic CCSP-rTetA/TetOP-Cre/Pdia3loxp/loxp (ΔEpi-Pdia3)
mouse to delete Pdia3 specifically in lung epithelial cells. Mice carrying TetOPCre/Pdia3loxp/loxp or CCSP-rTetA/TetOP-Cre were used as littermate controls (Ctr).
Characterizations of these mice are described elsewhere [6]. All mice were kept on
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doxycycline for the length of the experiment beginning seven days prior to IAV infection
to ensure ablation of Pdia3 throughout the infection protocol (Fig 5A). Our previous work
with these transgenic mice showed clear decrease of PDIA3 following doxycycline
exposure in the lung epithelial cells [6]. RT-qPCR analysis of viral transcripts (IAV-PA,
-HA, and –NA) in lung extracts showed significantly decreased viral load as evidenced from
the influenza markers that are examined in ΔEpi-Pdia3 mice compared to Ctr mice (Fig
5B-D). Strikingly, Western blots showed that HA protein levels were significantly
decreased following lung epithelial Pdia3 ablation (Fig 5E, Fig S5). Accordingly, these
decreases in HA also resulted in decreased HA oligomers (150-200 kDa) in- ΔEpi-Pdia3
mice compared to Ctr mice (Fig 5F). Taken together these results suggest lung epithelial
PDIA3 plays an important role in efficient HA production and IAV burden in vivo.

We next determined if this decrease in viral burden due to Pdia3 deletion led to a
concomitant decrease in influenza-induced inflammation. Analysis of chemokines in the
lung tissues showed that production of neutrophil chemoattractant CXCL1 and
dendritic/macrophage chemoattractant CCL20 were decreased in IAV-infected ΔEpiPdia3 mice when compared with IAV-infected Ctr mice. (Fig 5G and H). Analysis of total
cells in bronchoalveolar lavage fluid (BALF) also showed a significant decrease in
inflammatory cell numbers in ΔEpi-Pdia3 mice infected with IAV as compared to Ctr mice
infected with IAV (Fig 5I). Quantitation of specific inflammatory cell types revealed
significant attenuation of total macrophages, neutrophils, and lymphocytes in IAV infected
ΔEpi-Pdia3 mice when compared with IAV infected Ctr mice (Fig 5J-L).

53

Ablation of Pdia3 in the lung epithelium attenuates influenza-induced airway
hyperresponsiveness (AHR)
Viral infection is known to increase methacholine sensitivity and AHR in mice
and humans [33-35]. Therefore, we examined the consequence of epithelial specific
deletion of Pdia3 on AHR to increasing doses of inhaled methacholine. Following the
saline (vehicle control for methacholine) challenge, peripheral airway resistance (G), but
not central airway resistance (Rn) or parenchymal tissue elasticity (H), was elevated in
control (Ctr) mice infected with IAV compared to mock infected Ctr mice, suggesting that
IAV caused dysfunction of the small airways and/or lung parenchyma [36] (Fig 6 A-C).
However, there was no increase in G in ΔEpi-Pdia3 mice infected with IAV. Furthermore,
methacholine challenges showed that IAV increased AHR as measured by changes in both
Rn and G; however, the severity of the AHR measured by both G and Rn was significantly
decreased in IAV-infected ΔEpi-Pdia3 mice (Figure 6D & E). This suggests that due to
IAV infection, the presence of PDIA3 increases responsiveness to methacholine and results
in constriction of the central and peripheral airways. Taken together these results suggest
that lung epithelial PDIA3 plays an important role in the establishment of IAV burden,
inflammation, and AHR

DISCUSSION
The pathogenesis of IAV involves a complex interplay between numerous host
and viral factors [37]. Additional understanding of the influenza virus as well as the host
cellular pathways utilized by IAV would provide valuable insight toward the development
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of novel therapeutic and preventative modalities less dependent on viral antigenic shift and
drift.

Recent studies have suggested that several PDIs play important roles in influenza
pathogenesis [17, 38]. However only the calnexin/calreticulin associated, glycoprotein
specific PDIA3 is known to be directly involved in the processing of IAV hemagglutinin
(HA), one of the major antigenic determinants of the virus [15, 17, 39]. Disrupting this
PDIA3-HA interaction provides an intriguing therapeutic target. While there is a large
amount of diversity in IAV hemagglutinin [40], the cysteine residues involved in disulfide
bonding are highly conserved (Fig S3), highlighting their importance in the structure and
function of HA.

Herein, we show that PDIA3 levels are increased following IAV infection, and
PDIA3 transcript levels are upregulated compared with other PDIs. Treatment with a
reversible PDI inhibitor LOC14 results in altered -S-S- bonds in both H1 and H3 HA along
with associated alterations of HA maturation and subsequent decreases in markers of viral
infection, demonstrating potent anti-influenza activity independent of viral strain. While
LOC14 is known to be a potent UPR activator[23], 24 hours post LOC14 treatment dosed
cells do not show signs of exacerbated cellular stress or enhanced apoptosis. Furthermore,
genetic ablation of Pdia3 in the airway epithelium, the primary site of influenza infection,
results in a similar phenotype of diminished overall viral load. Finally, we also show
restoration of normal lung mechanics following Pdia3 ablation in IAV infected mice.
Taken together our results suggest the importance of lung epithelial PDIA3 in formation
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of -S-S- bonds of IAV HA and subsequent establishment of IAV infection, airway
inflammation and AHR.

PDIs play critical roles in oxidative folding of proteins, catalyzing and
isomerizing disulfide bonds [7]. PDIA3 is required for the efficient folding of HA by
catalyzing and isomerizing disulfide bonds and ensuring proper cysteine pairings [15]. Past
work has demonstrated the necessity of these disulfides in the proper folding of HA, as
well as in the formation of the HA trimer and its transport through the secretory system of
the cell to the plasma membrane [14, 41], potentially linking oxidative folding to viral
assembly. LOC14 treatment led to significant alterations of the disulfide bonds of both H1
and H3 HA. Regardless of IAV strain, HA cleavage occurs after it has left the ER, either
in the Golgi or at the cell surface [42, 43]. Following LOC14 treatment we observe a
marked decrease in HA1, which suggests that altered oxidative folding prevents the normal
proteolytic processing of HA. Studies involving HA mutants lacking the ability to form
proper disulfide bonds demonstrate retention of the mutant misfolded HA in the ER and
enhanced proteasome-mediated degradation [14, 44-47].

HA is known to oligomerize to its SDS resistant trimeric conformation within the
ER regardless of ATP concentration, blocked transport from the ER, temperature
alterations, and the trimming of carbohydrate side chains[31].

This suggests that

trimerization is largely dependent on the acquisition of the proper tertiary structure of the
HA0 monomers. Impairment of proper disulfide bond formation has been shown to hinder
detection of correctly folded trimeric HA; moreover, Pdia3 deletion has shown to cause a
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decreased number of HA molecules acquiring its trimeric structure [14, 15]. We found that
PDI inhibition with LOC14 resulted in a similar phenotype, causing a marked decrease in
the appearance of high molecular weight SDS resistant HA species combined with
concomitant increases in monomeric H1-HA, though no increase in monomeric H3-HA
was observed.

Collectively, these results suggest that alteration in HA maturation

(oligomerization) is driven by intramolecular -S-S- bonds rather than other protein
modifications.

Interestingly we observe variable decreases in HA0 levels following LOC14
treatment for both H1-HA and H3-HA on Western blots. These variations may be due to
differences in the amount of protein used as well as different gel-running time for the
various Western blots.

While LOC14 treatment has an effect on the folding of HA, at this juncture, it is
not possible to determine which PDIs are being affected. LOC14 has been extensively
characterized against PDIA1, the prototypical member of the PDI family. It has been
proposed in the literature that LOC14 would be effective against other PDI family members
owing to high sequence homology and conservation of the active site, though this has yet
to be verified [18, 22]. siRNA experiments have shown PDIA1, 3, and 4 all play some role
in influenza infection, leading to significant decreases in viral replication, though no viral
proteins that reach the plasma membrane through the secretory pathway were examined
[38]. Thus the effects we see could be the result of LOC14 inhibiting multiple PDIs, though
PDIA3 is the only PDI directly involved in HA maturation [15]. However, a lack of
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specificity would theoretically result in substantial loss of PDI activity in cell lysates
treated with LOC14; while we observe significant decreases in PDI activity there is
nonetheless high background signal in lysates of cells treated with LOC14. This could
suggest that DiE-GSSG might be able to act as a substrate for other redox active cellular
proteins such as thioredoxins or glutaredoxins. Another possibility is an alteration of the
equilibrium between the bound and unbound inhibitor, the inhibitory capacity of LOC14
may be altered under diluted assay conditions. Further refinement and experimentation are
needed to accurately assess the biological capacity of LOC14 on PDI activity in influenzainfected cells.

LOC14’s lack of specificity toward a single PDI may also explain differences in
chemokine levels following treatment. Various PDIs might be involved more directly in
not only the production, but also the secretion of these chemokines or other cytokines, for
example, PDIA1 is found at high levels in the secretory granules of eosinophils [48], and
we have previously shown siRNA knockdown or ablation of Pdia3 in lung epithelial cells
decreases various cytokine levels, and alters oxidative folding of Eotaxin, EGF and
Periostin in mice [6].

The lack of specificity of LOC14 also leaves open the possibility of inhibiting not
only PDIs but also other oxidoreductases with thioredoxin fold domains[18, 49].
Thioredoxin reductases utilize selenocysteine to mediate their effects[50], as such the
potential interactions with LOC14 are harder to predict. Direct interaction between these
proteins and viral HA is unlikely, as they are not found in high abundance within the ER[49,
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50]. Previous work has demonstrated treatment with glutathione derivatives significantly
decreases influenza replication, which was attributed to an alteration in the redox state of
PDIs[51], suggesting the importance of the redox buffering capacity of the cell for
influenza replication. We predict that if LOC14 is able to interact with these redoxbuffering enzymes it would allow for the possibility of additional indirect inhibition of
PDIs, though extensive experimentation would be required to accurately determine
additional LOC14 targets.

To investigate the role of PDIA3 during IAV infection in vivo we deleted Pdia3
specifically in the lung epithelium. Our results show deletion of Pdia3 in the lung
epithelium significantly decreased overall viral load. Moreover, we show Pdia3 deletion
significantly attenuates IAV mediated airway inflammation and AHR. Pdia3 deletion
strikingly ablates increases in peripheral airway resistance found in control mice following
IAV infection. Viral infection is known to induce or exacerbate AHR in humans and mice
[33, 34], and present data provides strong evidence that deletion of PDIA3 in the lung
epithelium leads to relevant improvements of lung mechanics. The protection against
changes in Rn and G during methacholine challenge suggest the changes are due to reduced
airway narrowing of both large and small airways[52, 53]. While the lack of effect on H
suggests that is does not change the severity of airway closure during methacholine
challenge [54]. Though it remains possible the reduction in AHR is simply due to decrease
in viral burden following ablation of Pdia3

Interestingly HA levels were severely decreased after ablation of PDIA3, pointing
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to a potential role for PDIA3 in influenza entry into the cell. In certain cells PDIA3 found
on the plasma membrane is known to play an important role in gamete fusion, act as a
receptor for certain vitamins, and facilitate HIV entry [55-57]. However experiments using
cell impermeable PDI inhibitors showed little impact on influenza replication, suggesting
PDIA3’s role in influenza propagation may be limited to protein maturation in the ER [38].

In conclusion, our findings support that PDIA3 activity is involved in IAV
replication, specifically in the oxidative folding of IAV HA. Interestingly this effect
appears to occur independent of influenza strain. Lung epithelial specific ablation of Pdia3
suggested that IAV infection and spread may require Pdia3 in vivo and ablation of Pdia3
also decreased inflammatory markers as well as virus load in the lung. These results suggest
that inhibiting PDIA3 during influenza infection may decrease viral load and improve lung
mechanics. Furthermore, we have shown that a reversible, small molecule PDI inhibitor
LOC14 has anti-influenza activity and may form a potential basis for future anti influenza
therapeutics by inhibiting PDIs.

MATERIALS AND METHODS
Ethics statement
All animal studies were approved by the University of Vermont Institutional
Animal Care and Use Committee and carried out in accordance with the Guide for the Care
and Use of Animals of the National Institutes of Health. The University of Vermont adheres
to the “U.S. Government Principles for the Utilization and Care of Vertebrate Animals
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Used in Testing, Research, and Training”, “PHS Policy on Humane Care and Use of
Laboratory Animals”, “USDA: Animal Welfare Act & Regulations”, and “the Guide for
the Care and Use of Laboratory Animals”. The University is accredited by the Association
for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).
University of Vermont’s PHS Assurance Number: A3301-01, expiration date: October 31,
2021. University of Vermont IACUC was approved on July 30, 2013, and the animal
protocol number is 13-063. The de novo renewal was approved on July 17, 2018, and the
animal protocol number is 13-063.

Viruses
Influenza A virus Puerto Rico 8/34 (H1N1) (10100374) and A X-31, A/Aichi/68
(H3N2) (10100375) were purchased from Charles River.

Cells and treatments
Primary MTECs were isolated and cultured from age and sex matched wild type
(WT) C57BL/6NJ mice as previously described [6]. Cells were plated at 2 × 106 cells/dish
and when greater than 90% confluent, infected with mouse-adapted H1N1 influenza A
virus Puerto Rico 8/34 (PR8) or H3N2 A X-31, A/Aichi/68 (X31) at 2.5 Egg infectious
units (EIU)/cell in a DMEM/F12 (Gibco) growth factor–free medium. Ultraviolet light
(UV)–irradiated virus that was replication-deficient (mock) was used as a control.
Following infection the cells were incubated for 1 h at 37 ºC, the plates were then washed
twice with 2 mL PBS to remove unbound virus, and supplemented with growth factor–free
medium. MTECs were pretreated for 2 h with 10 μM LOC14 (Tocris, 5606), during viral
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infection, and 1 h post viral infection, DMSO was used as a control. All treatments were
performed in growth factor–free medium.

Transgenic Mice
Bitransgenic mice carrying the rat club cell secretory protein (CCSP) promoter 5′
to the open reading frame for the reverse tetracycline transactivator (CCSP-rtTA; line 1,
which in adult lungs is expressed in bronchiolar and type II epithelial cells) [58] plus 7
tetracycline operon 5′ to the open reading frame for Cre recombinase (TetOP-Cre) mice
were provided by Dr. Whitsett (Cincinnati Children's Hospital) [59]. CCSP-rtTA+, TetOPCre+ mice were bred with mice carrying the Pdia3loxp/loxp alleles [60]. Mice expressing
CCSP-rtTA/TetOP-Cre/Pdia3loxp/loxp were used to ablate Pdia3 from lung epithelial cells
(denoted as ΔEpi-Pdia3) by feeding doxycycline-containing chow (6 g/kg; Purina Diet
Tech, St Louis, Mo) 7 days before exposure to virus. Mice were maintained on
doxycycline-containing food until completion of the experiment. Double-transgenic
littermates containing either CCSP-rtTA/TetOP-Cre or CCSP-rtTA/Pdia3loxp/loxp (Ctr mice)
and fed doxycycline-containing food were used as controls in the experiments.

Assessment of AHR
Mice were anesthetized by IP injection of pentobarbital solution (90 mg/kg),
tracheotomized with an 18-gauge cannula, then mechanically ventilated at a rate of 200
breaths/min using a FlexiVent computer controlled small animal ventilator (SCIREQ).
While on ventilators mice received the paralytic, pancuronium bromide. Parameters of
Newtonian resistance (Rn), tissue dampening (G), and elastance (H) were calculated as
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previously described [61]. Airway hyperresponsiveness is represented as the average of the
three peak measurements for each animal, obtained at increasing methacholine doses.

Bronchoalveolar lavage processing
Bronchoalveolar lavage fluid (BALF) was collected by lavaging lungs with 1.0
mL of sterile PBS. Cells were isolated by centrifugation, and total cell counts were
determined using a hemocytometer (Hausser Scientific) on an Inverted Infinity and Phase
Contrast Microscope (Fisher Scientific). Differential cell counts were obtained via
cytospins using Hema3 stained (Fisher Scientific) total cells. Differentials were performed
on a minimum of 300 cells/animal.

Analysis of mRNA expression
Right lung lobes were flash-frozen and pulverized, and total RNA was isolated
using Qiazol Lysis Reagent (Qiagen) and purified using the RNeasy kit (Qiagen). One
microgram of RNA was reverse transcribed to cDNA for quantitative assessment of gene
expression using SYBR green (Bio-Rad). Expression values were normalized to indicated
housekeeping gene(s). The primers used in this study are listed in Supplemental table 1.

Western blot analysis
Following dissection, right lung lobes were flash-frozen for protein or mRNA
analysis. Lungs were pulverized and lysed in buffer containing 20 mM Tris·HCl (pH 8.0),
100 mM NaCl, 0.5% Nonidet P-40, 10% glycerol, and 1% protease inhibitor cocktail
(Sigma-Aldrich, P8340) (v/v), 1% phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich,
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P5726, P0044) (v/v). Proteins from cell lysates were prepared in the same buffer. Insoluble
proteins were pelleted via centrifugation. Following protein quantitation of the supernatant,
samples were resuspended in loading buffer with dithiothrietol and resolved by SDSPAGE. Proteins were transferred to PVDF, and membranes were probed using a standard
immunoblotting protocol. Protein quantification of supernatant was determined using DC
Protein Assay (Bio-Rad, 5000116). Samples were resuspended in loading buffer with
dithiothrietol and resolved by SDS-PAGE. The quantification of protein expression was
performed by densitometry using Image Studio Lite software (LI-COR Biosciences).
Antibodies used for western blots can be found Supplemental table 2

Image processing
Digital images were acquired using an Amersham Imager 600RGB (GE).
Photoshop (CC 2018; Adobe) and Illustrator (CC 2018; Adobe) were used to assemble the
figures. Samples were run on the same gel. When required, brightness and contrast were
adjusted equally in all lanes.

ELISA
Lung protein samples were assayed for CXCL1 (DY453, R&D) and CCL20
(DY760, R&D) by ELISA according to the manufacturer's instructions.

Non-reducing gel electrophoresis
Lung homogenates were resuspended in loading buffer without the reducing agent
dithiothrietol (DTT). A separate set of samples were resuspended in loading buffer with
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DTT and incubated at 95°C for 10 minutes to reduce the disulfide bonds. The samples were
resolved by SDS-PAGE and subjected to western blot analysis as described.

Immunofluorescence
Following euthanization, left lobes were fixed with 4% paraformaldehyde, stored
at 4°C overnight for fixation of the tissue, mounted in paraffin, and 5 μm sections were
affixed to glass microscope slides for histopathology as previously described [61]. Sections
were prepared for immunofluorescence by deparaffinizing with xylene and rehydrating
through a series of ethanols. For antigen retrieval, slides were heated for 20 min in 95°C
pH 6.0 sodium citrate buffer with 0.05% TWEEN-20 then rinsed in dH2O. Sections were
then blocked for 1 hr in 1% BSA in PBS, followed by incubation with primary antibody
for PDIA3 (LSBio, LS-B9768) at 1:300, overnight at 4°C. Slides were then washed 3x5min
in PBS, incubated with Alexafluor 647 at 1:1000 in 1% BSA, and counterstained with
DAPI in PBS at 1:4000 for nuclear localization. Sections were imaged using a Zeiss 510META confocal laser-scanning microscope. Images were captured at x40 magnification in
oil immersion. The image files were converted to Tiff format. Brightness and contrast were
adjusted equally in all images.

PDIA3 activity assay
PDI disulfide reduction activity was monitored in PDI assay buffer containing
0.1 M potassium phosphate buffer pH 7.0 and 2 mM EDTA by adding 10ng recombinant
human PDIA3 (Prospec, ENZ-474) or 2μg MTEC lysate to 150mM DiE-GSSG (Cayman,
11547) in the presence of 5 μM DTT. DiE-GSSG is comprised of two eosin molecules
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attached to oxidized glutathione, resulting in proximity quenching of the eosin molecules.
Upon reduction of the -S-S- bond (i.e. PDIs, DTT), fluorescence emission of eosin
increases dramatically [25]. The increase in fluorescence signal was monitored at 528 nm
with excitation at 485 nm using a Synergy HTX plate reader (Biotek). The total reaction
volume was 100 μL. For inhibition of PDIA3 the reaction mixture was incubated with
LOC14 (Tocris, 5606) at the indicated concentrations for 30 minutes on ice prior to the
addition of DiE-GSSG. IC50s were calculated using GraphPad Prism (version 7.0,
GraphPad); briefly initial rates of fluorescence over time were determined over the first 10
minutes for indicated inhibitor concentrations, IC50s were then determined using threeparameter non-linear regression.

Biotin Switch Assay
To block free sulfhydryls, cells were lysed in buffer containing 20 mM Tris·HCl
(pH 8.0), 100 mM NaCl, 0.5% Nonidet P-40, 10% glycerol, 1% protease inhibitor cocktail
(Sigma-Aldrich, P8340) (v/v), 1% phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich,
P5726, P0044) (v/v), and 1 mM N-Ethylmaleimide (NEM) for 1 hour at ambient
temperature. Excess NEM was then removed via acetone precipitation. Briefly, Acetone
was cooled to -20ºC. Four times the sample volume was added to protein samples. Samples
were then vortexed and incubated overnight at -20 ºC. Precipitated protein was pelleted by
centrifugation at 14,000 x g for 10 minutes. The supernatant was aspirated and the resulting
pellet was suspended in buffer containing 20 mM Tris·HCl (pH 8.0), 100 mM NaCl, 0.5%
Nonidet P-40, 10% glycerol, 1% SDS, and 1% protease inhibitor cocktail (Sigma-Aldrich,
P8340) (v/v), 1% phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich, P5726, P0044)
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(v/v). Upon resuspension disulfides were reduced with 20 µM DTT and newly formed
sulfhydryl groups were labeled with 1 mM 3-(N-maleimido-propionyl) biocytin (MPB)
(Invitrogen, M1602) for 1 hour at ambient temperature. Excess DTT and MPB were
removed via acetone precipitation. The labeled lysate was precipitated using NeutrAvidin
agarose resin (Thermo Scientific, 29200) and subsequently probed using an anti-HA
antibody. As a reagent control, lysates from cells were incubated with DMSO and subjected
to the same procedures.

Flow Cytometry
The following antibodies were used for flow cytometric staining: anti-IAV NP
(Abcam, ab20921), Mouse IgG1 isotype control (Abcam, ab91356). Intracellular staining
was performed using the BD Cytofix/Cytoperm kit (Becton Dickinson, 554714), according
to the manufacturer’s instructions. All samples were run on a Guava easyCyte HT
cytometer (Millipore) and analyzed using Flowjo (version 10.4.2, TreeStar)

Statistics
Data were analyzed by one-way analysis of variance (ANOVA) and a Tukey’s
post-hoc test to adjust for multiple comparisons, or student’s t test where appropriate.
Statistical analysis was performed using Graph Pad Prism (version 7.0, Graph Pad). A p
value ≤ 0.05 was considered significant. Data from multiple experiments were averaged
and expressed as mean values ± SEM.
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Microarray analysis
GEO2R (www.ncbi.nlm.nih.gov/geo/info/geo2r.html) was used to perform
comparisons on differentially expressed genes between influenza-infected samples and
normal controls on GSE63786 and GSE48466. GEO2R automatically performs a base 2
log transformation.

Caspase Assay
25ug of treated MTEC lysate was brought to 25ul with dH2O and 25ul CaspaseGlo 3/7-assay reagent (Promega, G8091) were mixed and incubated in the dark at ambient
temperature for 20 minutes. Total luminescence was monitored using a Synergy HTX plate
reader (Biotek). Values were expressed as relative luminescence units.

siRNA
Mouse type II epithelial cells (C10) were cultured as describe previously[17].
Cells were treated with Accell control small interfering (si)RNA (Dharmacon, D-00192002-05) or PDIA3 siRNA (Dharmacon, E-045187-00) as per manufactuers instructions for
24 hours prior to infection with influenza virus or UV-irradiated mock virus.

Immunoprecipitation
HBE cells were lysed in cells were lysed in buffer containing 20 mM Tris·HCl
(pH 8.0), 100 mM NaCl, 0.5% Nonidet P-40, 10% glycerol, 1% protease inhibitor cocktail
(Sigma-Aldrich, P8340) (v/v), 1% phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich,
P5726, P0044) (v/v). PDIA3 was precipitated using anti-PDIA3 antibody (Enzo Life
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Sciences, ADI-SPA-585-F) and Protein G agarose beads (Invitrogen, 15920010). As a
control, lysate from cells were incubated non-specific rabbit gamma globulin (Jackson
ImmunoResearch, 011-000-002) and subjected to the same procedures. Samples were run
on reducing gels.
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FIGURE LEGENDS
Figure 1: PDIA3 expression is increased following IAV infection.
A. Mice were infected intranasally with 2000 EIU of IAV or mock virus. Pdia mRNA
levels were measured in whole lung lysates 6 days post infection (n=4-5 mice/group). B.
Confocal immunofluorescence microscopy of mouse lung tissue sections 6 days post
infection with either IAV or mock virus stained with anti-PDIA3 antibody followed by
secondary antibody conjugated to Alexa 647. Nuclei were stained with DAPI. C.
Retrospective analysis of microarray data of Pdia1, 3, and 4 mRNA transcript levels (GEO
data set GSE63786) Data expressed as Log2 normalized counts. D. Retrospective analysis
of microarray data of PDIA3 mRNA transcript levels from (GEO data set GSE48466). Data
expressed as Log2 normalized counts, Data are expressed as means (± SEM) * p<0.05, **
p<0.01, *** p<0.001, **** p<0.001 by ANOVA. E. Western blot analysis of IAV HA:
PDIA3 interaction in HBE cells following PDIA3 immunoprecipitation. Numbers below
indicate average densitometry per group of WCL PDIA3 normalized to GAPDH F.
Western blot analysis of IAV HA and PDIA3 in mouse lung epithelial cells transfected

70

with scrambled (-) or Pdia3-specific siRNA (+). Numbers below indicate densitometry of
IAV HA normalized to β actin.

Figure 2: PDI inhibitor LOC14 inhibits PDIA3 and decreases influenza protein
production.
A. Kinetics of PDIA3 catalyzed reduction of DiE-GSSG in the presence of increasing
concentrations of recombinant PDIA3. B. Chemical structure of reversible PDI inhibitor
LOC14. C. Dose dependent inhibition of PDIA3 reductase activity with LOC14. Heattreated rPDIA3, alkylated (NEM) rPDIA3, and LOC14 without PDIA3 were included as
controls. D. IC50 of LOC14 for PDIA3 determined based on the initial rate of fluorescence
formation from C. E. Treatment regimen for LOC14 in MTEC cells. F. Percentage of
IAV NP+ primary mouse tracheal epithelial cells 24 hours post infection with IAV or mock
virus following treatment with LOC14 or vehicle control. G. EC50 of LOC14 determined
from percentage of infected cells from F. H. Significant decreases in PDI activity in the
cells treated with LOC14. ** p<0.01 by t test.

Figure 3: LOC14 treatment in primary mouse tracheal epithelial cells (MTECs)
decreases -S-S- of HA and viral burden.
A. Schematic representing the time points of IAV infection and LOC14 treatment. B.
Western blot analysis of PR8 HA0/HA1 of cells treated as in A. GRP94 was used as a
loading control. Duplicates (mock) and triplicates (IAV) of identical conditions are shown.
C. Schematic depicting biotin switch assay and subsequent labeling of reduced sulfhydryl
groups by MPB. D. Western blot analysis of thiol content of IAV HA following LOC14
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treatment by MPB labeling and neutravidin pulldown. E. Western blot analysis of HA
oligomerization following LOC14 treatment of IAV infected cells, samples analyzed by
reducing (+DTT) and non-reducing (-DTT) run on a SDS-PAGE. F. mRNA expression of
IAV PA from cell lysates of mock infected and IAV infected primary MTECs analyzed by
RT-qPCR. G. Percentage of IAV NP+ MTECs following LOC14 treatment, *p<0.05
compared to mock groups, #p<0.05 compared to IAV-VC group by ANOVA. H.
Percentage of IAV NP+ MTECs following exposure to LOC14 or vehicle control treated
supernatant from F, *p<0.05 compared to VC group by t test. I and J. mRNA expression
of Irf7 and Ccl20 from cell lysates of mock infected and IAV infected primary MTECs
analyzed by RT-qPCR. PCR results were normalized to housekeeping gene Gapdh.
*p<0.05 compared to mock groups, #p<0.05 compared to IAV-VC group by ANOVA.
Data are expressed as means (± SEM) of 3 samples per group.

Figure 4: LOC14 treatment alters oxidative folding of different HA in H3N2 serotype.
A. Western blot analysis of X31 HA0/HA1, GAPDH was used as a loading control (top
panel), Western blot analysis of thiol content of IAV HA following LOC14 treatment by
MPB labeling and neutravidin pulldown (bottom panel). B. Western blot analysis of HA
oligomerization following LOC14 treatment of IAV infected cells, samples analyzed by
reducing (+DTT) and non-reducing (-DTT) run on a SDS-PAGE. C. mRNA expression of
IAV PA from cell lysates of mock infected and IAV infected primary MTECs analyzed by
RT-qPCR, *p<0.05 compared to mock groups, #p<0.05 compared to IAV-VC group by
ANOVA. D. Percentage of IAV NP+ MTECs following LOC14 treatment by flow
cytometry, *p<0.05 compared to mock groups, #p<0.05 compared to IAV-VC group by
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ANOVA. E. Percentage of IAV NP+ MTECs following exposure to LOC14 or vehicle
control treated supernatant from E by flow cytometry, *p<0.05 compared to VC group by
t test. F and G. mRNA expression of Irf7 and Ccl20 from cell lysates of mock infected and
IAV infected primary MTECs analyzed by RT-qPCR. PCR results were normalized to
housekeeping gene Gapdh. *p<0.05 compared to mock groups, #p<0.05 compared to IAVVC group by ANOVA. Data are expressed as means (± SEM) of 3 samples per group.

Figure 5: Ablation of Pdia3 in the lung epithelium attenuates viral burden and
inflammation in mice.
A. Schematic representing the time points of IAV infection and doxycycline treatment and
euthanasia of mice. B-D. Analysis of mRNA for influenza proteins (PA, HA and NA) in
whole lung lysate by RT-qPCR, results normalized to the geometric mean of housekeeping
genes Pp1b and Gapdh, *p<0.05 compared to mock groups, #p<0.05 compared to IAVCtr group by ANOVA. E. Western blot analysis of IAV HA in Ctr and ΔEpi-Pdia3 mice,
GRP94 was used as a loading control. * Indicates nonspecific band. F. Western blot
analysis of HA oligomerization following ablation of PDIA3 in the airway epithelium,
samples analyzed by reducing (+DTT) and non-reducing (-DTT) SDS-PAGE. G and H.
ELISA for CXCL1 and CCL20 from whole lung homogenates, *p<0.05 compared to mock
groups, #p<0.05 compared to IAV-Ctr group by ANOVA. I-L. Analysis of inflammatory
and immune cells in the BALF by hema 3 stain and differential counting, *p<0.05
compared to mock groups, #p<0.05 compared to IAV-Ctr group by ANOVA. Data are
expressed as means (± SEM) of 6–10 mice/group.
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Figure 6: Ablation of Pdia3 in the lung epithelium attenuates influenza-mediated
methacholine induced AHR.
A-C. Assessment of AHR via a forced oscillation technique in Ctr and ∆Epi-Pdia3 mice.
Saline was administered to determine baseline Newtonian resistance (Rn), tissue resistance
(G), and tissue elastance (H), *p<0.05 compared to mock groups, #p<0.05 compared to
IAV-∆Epi-Pdia3 group by ANOVA. D-F. Methacholine (12.5-50 mg/mL) induced AHR
represented as percent increase from saline following exposure to increasing doses of
methacholine. *p<0.05 compared to mock groups, #p<0.05 compared to IAV-∆Epi-Pdia3
group by ANOVA. Data are expressed as means (± SEM) of 6–10 mice/group.

SUPPORTING INFORMATION
Figure Legends
S1 Fig. GSE63786 PDI transcript levels.
A. Retrospective analysis of microarray data of Pdia mRNA transcripts from GEO data set
GSE63786. Data expressed as Log2 normalized counts. * p≤0.05, ** p≤0.01, *** p≤0.001,
**** p<0.001 by ANOVA. B. Quantification of PDIA3 expression from Fig 1E WCL.
Protein bands were quantitated by densitometry, expressed relative to GAPDH, and
normalized to mock-infected cells. Data are expressed as means (± SEM) of 3 samples per
group. C. Quantification of IAV H1 HA expression from Fig 1F. Protein bands were
quantitated by densitometry, expressed relative to β actin, and normalized to siControl
treated IAV infected cells.
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S2 Fig. Flow cytometric dot plots.
A. Quantification of HA expression from Fig 3B. Protein bands were quantitated by
densitometry, expressed relative to GRP94, and normalized to vehicle control treated
mock-infected cells. Data are expressed as means (± SEM) of 2-3 samples per group.
B. Representative flow cytometric dot plots corresponding to PR8 NP+ cells in figure 3H.
C. Representative flow cytometric dot plots corresponding to PR8 NP+ cells in figure 3I.
D. Western blot analysis of cellular stress markers following LOC14 treatment. E. Caspase
3/7 activity, measured by a luminescence assay, following LOC14 treatment. *p<0.05
compared to mock groups by ANOVA

S3 Fig. BLAST alignment of IAV hemagglutinin sequences.
A. Alignment of H1N1 HA sequences from 1934 to 2009. B. Alignment of HA sequences
from various influenza serotypes. Boxes indicate conserved Cysteine residues. (Clustal
Omega v1.2.1)

S4 Fig. Flow cytometric dot plots.
A. Quantification of HA expression from Fig 4A. Protein bands were quantitated by
densitometry, expressed relative to GRP94, and normalized to vehicle control treated
mock-infected cells. Data are expressed as means (± SEM) of 2-3 samples per group.
*p<0.05 compared to mock groups, #p<0.05 compared to IAV-VC group by ANOVA.
A. Representative flow cytometric dot plots corresponding to X31 NP+ cells in figure 4E.
B. Representative flow cytometric dot plots corresponding to X31 NP+ cells in figure 4F.
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S5 Fig. Quantification of HA-western blots

Quantification of HA expression from Fig 5E. Protein bands were quantitated by
densitometry, expressed relative to GRP94, and normalized to mock infected Ctr mice.
Data are expressed as means (± SEM) of 3-5 samples per group. *p<0.05 compared to
mock groups, #p<0.05 compared to IAV-Ctr group by ANOVA.

S1 Table. List of oligonucleotides used in this study

S2 Table. List and origin of antibodies used in this study
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ABSTRACT
Influenza (IAV) neuraminidase (NA) is a viral glycoprotein that plays a critical role
in viral exit from the cell. NA, like other IAV proteins, undergoes extensive disulfide bond
formation and these bonds are required for proper function.

We have recently

demonstrated the significance protein disulfide isomerase (PDI)A3 plays in proper
oxidative folding of IAV hemagglutinin, another major viral glycoprotein stabilized by
numerous disulfide bonds. However, it not known if PDIs play a role in NA maturation or
if these interactions represent a putative target for the treatment of influenza infection.
Here we show PDIA3 directly interacts with IAV NA and a cell line with CRISPR based
knock out of PDIA3 showed decreased NA levels. Treatment with the reversible PDI
inhibitor LOC14 alters oxidative folding and oligomerization of NA in both H1N1 and
H3N2 infected lung epithelial cells. Moreover, we demonstrate LOC14 treatment is nontoxic and significantly attenuates the influenza induced pro-inflammatory response
decreasing both inflammatory infiltrates in the lung as well as inflammatory cytokine levels
in IAV infected mice despite strain specific effects on overall viral burden. These results
suggest PDI activity is needed for effective influenza pathogenesis, via the NA activity and
in vivo inhibition of PDI activity possibly represents a novel platform for the development
of future host based antiviral therapies.
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INTRODUCTION
The influenza A virus (IAV) causes severe respiratory illness and has a worldwide
impact[1]. While vaccination and therapeutics are available, they are often rendered
ineffective due to accumulation of mutations in the viral genome[1]. One potential
strategy to circumvent this type of mutational resistance is targeting the host proteins or
post-translational processes utilized by the virus during propagation. The relationship
between IAV and host protein disulfide isomerases (PDIs), a family of proteins involved
in disulfide bond formation, is well established[2-4]. Disulfide bonds play an important
role in protein stability[5, 6] and viruses often utilize redox active host chaperone proteins
to assist in their protein folding[7].

PDIs are major disulfide catalyzing family of enzymes in mammalian cells[8]. One
isoform PDIA3 is known to be required for efficient folding of IAV hemagglutinin (HA)
in vitro[2], and we have recently demonstrated PDIA3s importance in active infection in
vivo[3]. A recent study has also shown specific overexpression of PDIA3, rather than other
PDI isoforms, yields improved stability of HA[9]. While other PDI isoforms are known to
play a role in IAV protein expression, the exact nature of that role remains unknown[4].

We have shown treatment with the reversible PDI inhibitor LOC14[10] in vitro
significantly alters the oxidative folding of IAV HA leading to disruptions in HA
maturation and also virus-induced inflammatory cytokine production[3].

However,

whether these disruptions in disulfide bond formation are limited to HA remain unknown.
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In order to further gain insight of this phenomenon, we investigated IAV Neuraminidase
(NA) of Influenza A Virus (IAV). NA is an homotetrameric viral enzyme found on the
surface of the virion[11]. NA is a glycoprotein stabilized by 32 disulfide bonds once fully
matured and is known to traffic through the endoplasmic reticulum (ER), the primary site
of localization of PDI [8, 12].

Active NA is required for viral release, cleaving sialic acid residues from cell
surface proteins and lipids to prevent viral aggregation on the cell[11, 12]. Given the role
of NA in the viral life cycle it is unsurprising that NA is a prominent target for antiinfluenza therapies. NA inhibitors are currently front-line therapeutic options for influenza
treatment[12]; however, their effectiveness is often limited by rapid viral mutation[13] and
a limited window of application. While NA has been extensively studied an increased
understanding of NA post-translational oxidative modifications may provide additional
avenues for potential therapeutic targets

The structure of NA is largely conserved across multiple influenza strains[12].
individual NA monomers as well as the tetramers are stabilized by numerous conserved
disulfide bonds[14].

The maturation of NA and HA are similar, both are surface viral

glycoprotein that traffic through the secretory pathway of the infected cell[11]. While the
role of PDIs, specifically PDIA3, in HA maturation are well established, it is unclear what
role, if any, PDIs play during NA disulfide bond formation.
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In this study, we provide evidence that PDIA3 and IAV-NA interact with one
another. We also show DPDIA3 CRISPR lines alters NA oligomerization. Additionally,
we demonstrate treatment of IAV-infected primary mouse tracheal epithelial cells
(MTECs) with the reversible PDI inhibitor LOC14[10] resulted in the alteration NA
disulfide bonds. This deficiency in disulfide bond formation decreased tetrameric NA and
subsequent NA activity. Treatment of IAV infected mice with LOC14 decreased viral
burden, inflammation, and pro-inflammatory cytokine production in vivo. These results
demonstrate that PDIA3 is a modulator of IAV-NA activity and inhibiting PDIs in vivo
decreases both IAV burden and subsequent pro-inflammatory responses, that leads to acute
lung injury.

RESULTS
Comparison of novel PDI inhibitors on PDIA3
We have recently demonstrated the reversible PDI inhibitor LOC14[10] has
inhibitory action against PDIA3[3]. Since this report, numerous other compounds have
been characterized as PDIA3 inhibitors, however none have been compared against
LOC14(Fig 1A). We compared three compounds: Eupatorin, Eupatorin-5-methyl ether,
and Isoquercitin (Fig 1A), all plant flavonoids believed to interact with the b’ domain of
PDIA3[15]. Reduction of Dieosine-diglutathione (DiE-GSSG) has been previously used
as a substrate to determine PDI activity[16, 17].

This assay shows Eupatorin and

Eupatorin-5-methyl ether show inhibitor effects at high concentrations (IC50 values of
66µM and 133µM respectively), while Isoquercitin has an IC50 of approximately 29 µM
(Fig 1B-D, Table 1). We then performed a direct comparison of the inhibitors on PDIA3,
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20µM of each inhibitor was incubated with 10ng of PDIA3(Fig 1E). Relative activity was
determined by comparison against PDIA3 incubated with the appropriate vehicle control
for each inhibitor. Taken together these results indicate the reversible PDI inhibitor LOC14
is the most effective inhibitor of PDIA3.

PDIA3 interacts with IAV NA
NA is known to be stabilized by numerous disulfide bonds [12, 14] and a BLAST
alignment demonstrates the cysteine residues involved in disulfide bonds show complete
conservation across examined influenza strains (Sup Fig. 1). In order to characterize any
PDIA3:NA interaction we performed co-immunoprecipitation experiments in human A549
adenocarcinoma alveolar basal epithelial cells after IAV infection or transfection with a
GFP tagged IAV NA (NA-GFP).

Analysis of the immunoprecipitations revealed that

PDIA3 interacted with NA in both the H1N1 infection model as well as the transfection
system as evidenced by immunoprecipitation and subsequent western blot analysis of
immunoprecipitated samples as well as whole cell lysates (WCL) (Fig 2A and B). To
determine whether PDIA3 expression impacts IAV- NA a stable CRISPR/Cas9 A549 cells
deficient in PDIA3 were infected with either H1N1 PR8 or H3N2 X-31 or respective mock
control. We found significant decreases in IAV-NA expression via western blot in both
viral strains following PDIA3 ablated cell line (Fig 2C). Taken together these results
indicated that PDIA3 and IAV NA interact and proper expression of IAV NA is dependent
on the presence of PDIA3.
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LOC14 treatment alters oxidative folding of IAV NA
IAV NA is a viral enzyme responsible for cleaving sialic acid residues of
glycoproteins, enabling viral exit from the infected cell[11, 12].

We monitored

recombinant-NA (rNA) activity by monitoring cleavage of (4-Methylumbelliferyl)-α-D-Nacetylneuraminic acid (MUNANA) to methylumbelliferone (4MU)[18] in the presence or
absence of disulfide reducing agent . Cleavage of MUNANA by neuraminidase yields the
fluorescent product 4-methylumbelliferone (4MU) enabling rapid assessment of NA
function. This assay showed that rNA alone yields high fluorescence activity, while rNA
incubated with the reductant DTT shows a loss of fluorescence activity. DTT itself had no
effect on the substrate (Fig 3A). These results indicated that disulfide bonds are potentially
required for NA activity.

We next examined the NA activity of acetone precipitated supernatants of IAV
infected isolated primary mouse tracheal epithelial cells (mTECs). Following LOC14
treatment we observed a significant decrease in the NA activity of the supernants,
suggesting the oxidative folding of NA was potentially altered (Fig 3B). We also observed
LOC14 has no direct effect on NA activity (Fig 3A). Mature functional NA is known to
exist as a homotetramer on the surface of the virion and the monomers and the tetramers
are stabilized by disulfide bonds. In order to examine the impact of LOC14 treatment on
NA oligomerization we utilized non-reducing SDS-PAGE, LOC14 treatment decreased in
high molecular weight X31 N2 NA species as compared to vehicle treated controls (Fig
3C). In order to more fully explore the effect of PDIA3 on the oxidative folding of NA we
utilized PDIA3 deficient human A549 CRISPR cells in both an infection and transfection
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model. Western blot (WB) analysis of WCL showed that in the absence of PDIA3 levels
of NA in the infection model were decreased, while in transfection model levels were more
or less constant (Fig 3D). We next determined whether the absence of PDIA3 would alter
-S-S- bonds of NA. We used a biotin switch assay to assess disulfides, briefly, by blocking
free cysteine sulfhydryl (-SH) groups using N-ethyl maleimide (NEM) and reducing -S-Sbonds with DTT, and then newly revealed -SH groups are labeled with biotin-conjugated
alkylating agent (MPB). This technique reveals high labeling of proteins with -S-S- bonds
and low labeling of proteins with -SH groups. Subsequent neutravidin pull-down and
Western blot analysis showed clear decreases in -S-S- bond formation in IAV-NA in both
models in PDIA3 deficient cells as compared to wild type A549 cells infected with IAV or
transfected with NA (Fig 3F). These results suggest that a decrease in oxidative folding in
the form of disulfide bonds of NA leads to impaired oligomerization.

LOC14 treatment decreases influenza viral burden and subsequent inflammation in
vivo
Wild type C57BL6/JN mice were treated three times with LOC14 via
intraperitoneal injection one-hour pre infection and 24- and 48-hours post infection with
H1N1 PR8 (Fig 4A). HA and ATF6 50 protein levels were decreased in a following
LOC14 injection (Fig 4B-C). RT-qPCR analysis of viral transcripts in isolated lungs
showed significantly decreased viral load in LOC14 treated mice (Fig 4D).

Analysis of total cells in BALF showed significant decrease in inflammatory cell
profiles in LOC14 dosed mice infected with IAV as compared to DMSO mice infected
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with IAV (Fig 4E) Quantitation of specific inflammatory cell types revealed significant
attenuation of macrophages, neutrophils, and lymphocytes (Fig 4E).

Moreover,

quantification of Irf7 transcripts also show significant decreases following LOC14
treatment (Fig 4F). Analysis of cytokines in the BALF showed that levels of the proinflammatory cytokines IL-6 and IL-1b, neutrophil maturation stimulator GCSF,
neutrophil chemo attractant CXCL1 (KC), and proinflammatory chemokine CCL20
showed largely dose dependent decreases following LOC14 treatment (Fig 4G-K).
Furthermore, no significant alterations in the serum alanine transaminase (ALT) levels
indicated that LOC14 did not induce any systemic toxicity (Fig 4L). Moreover, total protein
content of the BAL fluid of treated mice was decreased following LOC14 treatment
indicating more intact epithelial barrier as compared to vehicle treated mice. Owing to
complete conservation of cysteine residues between various strains of influenza (Sup Table
2) we sought to determine whether LOC14 also affected other neuraminidases e.g. N2. We
found similar decreases in inflammatory markers and immune infiltrates as H1N1
infection, though we observed less substantial effects on viral levels (Sup Fig 1). Taken
together these results suggested that LOC14 treatment decreases viral burden and
subsequent inflammatory response in vivo.

DISCUSSION
PDIs are known to play important roles in influenza pathogenesis[3, 4, 9, 19], we
have recently shown inhibition of PDI activity in vitro alters the maturation of IAV HA
[3]. Moreover, specific deletion of PDIA3 in airway epithelial cells results in leading to
disruptions of subsequent viral pathogenesis[3]. HA is not the only influenza protein
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containing disulfide bonds[11, 12], though the extent PDIs play in the their maturation is
not well known.

Herein, we demonstrate novel flavonoid-based PDI inhibitors[15] are not as
effective against PDIA3 as the reversible PDI inhibitor LOC14[10].

We show the

calnexin/calreticulin associated glycoprotein specific PDIA3 interacts with IAV NA, and
genetic ablation of PDIA3 results in decreases in NA protein production during viral
infection. LOC14 treatment alters the oxidative folding and oligomerization of NA
resulting in a loss of activity. Previous work has demonstrated the importance of disulfide
bonds in NA activity[14].

Furthermore, in vivo treatment of IAV infected mice

significantly altered viral pathogenesis, decreasing both viral load and subsequent
inflammatory response. Taken together our results suggest the importance of PDIA3 in
the oxidative folding of IAV NA and demonstrate the significance of host PDIs in viral
maturation and subsequent pathology.

The influenza virus causes yearly seasonal outbreaks and occasional recurrent
pandemics resulting in significant morbidity and mortality[20, 21], especially in certain atrisk groups such as asthmatics or the elderly[22, 23]. However, despite the impact of the
virus treatment options are largely limited. Besides vaccination there currently only three
classes of FDA approved influenza anti-viral drugs; M2 [24], NA [25], and PA
inhibitors[26]. Circulating influenza strains are largely resistant to M2 inhibitors[24, 27]
and resistance to NA inhibitors is increasingly common[25, 28].

The PA inhibitor

baloxavir marboxil represents the newest class of anti-influenza drugs, the first approved
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in nearly 20 years[29], though resistance to baloxavir emerged has quickly emerged[26,
30]. Each of these drugs targets a specific IAV protein, as such resistance can emerge
rapidly, a single amino acid substitution in the active site of IAV NA, H257Y, is enough
to reduce the effectiveness of oseltamivir by over 400-fold[31].

All viruses are obligate intracellular parasites and rely almost entirely on host
biochemical processes to propagate themselves. The PDI family plays an essential role in
the oxidative folding of proteins[8], and PDIA3 is known to be required for the efficient
folding of IAV HA catalyzing and isomerizing disulfide bonds and facilitating proper
cysteine pairings[2]. The lab has previously demonstrated a significant decrease in viral
burden in primary murine lung epithelial cells following siRNA mediated knockdown of
PDIA3 [19]. Previous work has shown proper disulfide bond formation is required for
IAV NA activity and proper formation of the protein[12, 14]. Our data shows PDIA3 also
interacts with IAV NA and its absence impacts NA levels in the infected cell. Furthermore,
PDI inhibition by LOC14 treatment potentially alters oxidative folding of NA and
significantly decreases NA activity. This suggests PDIA3 could play a similar role in NA
maturation as it does in HA maturation and demonstrates PDI inhibition impacts multiple
influenza proteins simultaneously. HA and NA both traffic through the secretory pathway
of the cell, going from the ER, the primary site of PDI expression, to the plasma membrane
via the Golgi complex[11]. The M2 protein is known to follow the same pathway and is
also stabilized by disulfide bonds, though whether these bonds involve interactions with
PDIA3 or any PDI are not currently known[32]. A recent study involving siRNA screens
demonstrated PDIA1 and 4, in addition to PDIA3 play a role in influenza infection[4].
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While no proteins that traffic through the secretory pathway were examined, the authors
found significant decreases in levels of IAV NP and M1. IAV NP is stabilized by transient
disulfide bonds, thought to prevent protein aggregation[33], during its maturation the M1
protein is not stabilized by disulfide bonds[34]. The exact nature of the protein-PDI
interactions and subcellular location is unclear and needs further exploration. The authors
also recapitulated these results with two PDIA1 specific inhibitors, PACMA31[35] and
Juniferidin[36]. LOC14 was first characterized as a PDIA1 inhibitor[10] and thus may
have a similar effect on NP and M2, though further experimentation is required. Exactly
what is happening to the proteins in question remains unknown. Production on either a
transcriptional or translational level may be affected, as PDIs have been demonstrated to
act as transcription factors[37]. Or perhaps more likely protein production occurs in a more
or less normal fashion, but maturation and oxidative folding are impacted, HA mutants
lacking the ability to form proper disulfide bonds are known to be retained in the ER and
show enhanced proteasomal degradation[38, 39].

While PDIs are expressed at numerous locations within the cell we believe it is
likely that protein maturation is impacted. PDI activity is required for HIV entry into the
cell, oxidatively modifying surface proteins of the virion to allow for viral entry[40],
however no such requirements are known for IAV entry. Previous studies have shown
treatment with Bacitracin a broad-spectrum cell impermeable PDI inhibitor does not impact
viral replication[4].
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Two independent groups were able to impact multiple IAV proteins with single
compounds targeting host PDIs[3, 4], this represents an improvement over current IAV
therapeutics which each target individual viral proteins[24-26]. While these therapeutics
can affect multiple IAV proteins by disrupting the viral replicative cycle, their effectiveness
is largely limited following the first 48 hours after infection[41], when the majority of viral
replication takes place[42]. As most viral protein production would occur during this time
frame the direct anti-viral effect of LOC14 treatment may also be governed by similar
restrictions.

Numerous cytokines are typically produced in response to viral infection including
proinflammatory IL-6, IL-1b, and IL-33, each having broad ranging effects in coordinating
and effectuating in the antiviral response[42-44]. We show dose dependent decreases in
all of these cytokines in the BAL fluid of treated mice, along with similar decreases in the
chemokine CXCL1, important in neutrophil recruitment[45]. These decreases suggest the
infection is more contained following LOC14 treatment as we see concomitant decreases
in viral readouts. However, we cannot rule out a direct immunomodulatory effect of PDI
inhibition. Cytokines and chemokines are often stabilized by disulfide bonds[46, 47], and
these bonds have been shown to be important for their function[48]. PDIs are known to
assist in the folding and maturation of various chemokines[49, 50], though their direct role
in the cytokines examined in this paper need to be determined. Still, given that PDIs are a
major disulfide mechanism in the cell[8] it is likely they play some role in cytokine
maturation. We do observe a difference in KC levels between BAL fluid and tissue lysate
of infected mice, which again may suggest a role for PDI inhibition in modulation cytokine
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release (Sup Fig 3), though other cytokines mirror the BAL fluid. Treatment with NA
inhibitors can also yield similar decreases in immune activation[51], this is likely due to
lower viral levels, as NA inhibitors are not known to directly modulate the immune
system[52] and their limited effectiveness when used after the period of initial viral
replication[51, 53].

Aberrant or over exuberant immune responses following viral infection, termed
cytokine storm, lead to excess level of proinflammatory cytokines and widespread tissue
damage and is often associated with worse clinical outcome[54].

The exact causes of

cytokine storm are not currently known but it commonly follows infection with pandemic
IAV strains and influenza strains of avian origin, though it can also occur during normal
seasonal outbreaks[54]. Treatments for cytokine storm include inhibitors of the elevated
cytokines in combination with anti-inflammatory drugs and displays conditional
effectiveness based on stratified patient groups[55]. Given the immunomodulatory effect
of LOC14 in both infectious and non-infectious models (Sup Fig 4), its effectiveness
against cytokine storm warrants further investigation.

LOC14 treatment has a direct anti-influenza effect and an apparent antiinflammatory effect, potentially altering oxidative folding of proinflammatory cytokines.
Suggesting PDI inhibition may be effective beyond the initial stages of infection
predominated by viral replication[41]. Additionally, given this methods reliance on host
proteins it opens up the possibility of utilizing PDI inhibitors as a broad spectrum anti-
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viral/anti-inflammatory treatment that can be utilized against novel infectious agents that
lack treatment options.

MATERIALS AND METHODS
Ethics statement
All animal studies were approved by the University of Vermont Institutional
Animal Care and Use Committee and carried out in accordance with the Guide for the Care
and Use of Animals of the National Institutes of Health. The University of Vermont adheres
to the “U.S. Government Principles for the Utilization and Care of Vertebrate Animals
Used in Testing, Research, and Training”, “PHS Policy on Humane Care and Use of
Laboratory Animals”, “USDA: Animal Welfare Act & Regulations”, and “the Guide for
the Care and Use of Laboratory Animals”. The University is accredited by the Association
for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).
University of Vermont’s PHS Assurance Number: A3301-01, expiration date: October 31,
2021. University of Vermont IACUC was approved on October 12, 2018, and the animal
protocol number is PROTO202000102, IACUC Legacy number 19-005. The de novo
renewal was approved on June 4, 2020, and the animal protocol number is
PROTO202000102, IACUC Legacy number 19-005.
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Viruses
Influenza A virus Puerto Rico 8/34 (H1N1) (10100374) and A X-31, A/Aichi/68
(H3N2) (10100375) were purchased from Charles River.

Cells and treatments
Primary MTECs were isolated and cultured from age and sex matched wild type
(WT) C57BL/6NJ mice as previously described[49]. Cells were plated at 2 × 106 cells/dish
and when greater than 90% confluent, infected with mouse-adapted H1N1 influenza A
virus Puerto Rico 8/34 (PR8) or H3N2 A X-31, A/Aichi/68 (X31) at 2.5 Egg infectious
units (EIU)/cell in a DMEM/F12 (Gibco, 21041025) growth factor–free medium.
Ultraviolet light (UV)–irradiated virus that was replication-deficient (mock) was used as a
control. Following infection, the cells were incubated for 1 h at 37 ºC, the plates were then
washed twice with 2 mL PBS to remove unbound virus and supplemented with growth
factor–free medium. MTECs were pretreated for 2 h with 10 μM LOC14 (Tocris, 5606),
during viral infection, and 1 h post viral infection, DMSO was used as a control. All
treatments were performed in growth factor–free medium.

Transfection
Cells were transfected using Lipofectamine 3000 transfection kit (Thermo Fisher
L3000015) as per manufactures instructions with the following modification; 2.5µg of
plasmid per plate, optional p3000 reagent was utilized, transfections were incubated for 4
hours. Human A549 adenocarcinoma alveolar basal epithelial cells were cultured as
suggested by the ATCC. Cells were plated at 4 x 105 cells/dish 24h prior to transfection.
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Immediately prior to transfection cells were washed with 1mL of PBS, and media replaced
with 1mL Opti-MEM (Thermo Fisher 31985070). After 4 hours transfection media was
aspirated and replaced with 2 mL Opti-MEM.

NA activity assay
NA activity assay was adapted from Leang et al[18]. The assay is based on NA
enzyme activity cleaving the 2′-(4-Methylumbelliferyl)-α-D-N-acetylneuraminic acid
(MUNANA) substrate (Cayman 16620) to release the fluorescent product 4methylumbelliferone (4-MU). NA activity was monitored in NA activity buffer
containing 33.3 mM 2-(N-morpholino)ethanesulfonic acid (MES) and 4 mM CaCl2, pH
6.5 by adding 50µL infected cell supernatant or 5µg of infected cell lysate to 300µM
MUNANA. The increase in fluorescence signal was monitored at 460 nm with excitation
at 355 nm using a Synergy HTX plate reader (Biotek). The total reaction volume was
100 μL. Rates were calculated using GraphPad Prism (version 8.4.1, GraphPad).

CRISPR lines
PDIA3 deficient A549 cells were purchased from Synthego (Synthego Corporation,
Menlo Park, CA). Cells were screened by plating 1 cell/well in a 96 well flat bottom plate.
Single cell wells were marked and monitored for growth. After approximately 4 doublings
cells were trypsinized and transferred to 6 well plates. Upon reaching ~70% confluency
cells were trypsinized and transferred to T75 flasks. PDIA3 levels were ascertained by
western blot.
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Bronchoalveolar lavage processing
Bronchoalveolar lavage fluid (BALF) was collected by lavaging lungs with 1.0 mL
of sterile PBS. Cells were isolated by centrifugation, and total cell counts were determined
using a Guava easyCyte HT cytometer (Millipore) and analyzed using Flowjo (version
10.4.2, Ashland, OR: Becton, Dickinson and Company). Differential cell counts were
obtained via cytospins using Hema3 stained (Fisher Scientific) total cells, on a minimum
of 300 cells/animal, or using a Guava easyCyte HT cytometer with a protocol adapted from
van Rijt et al[56]. Briefly, isolated cells were incubated with TruStain fcX (BioLegend
101320) to reduce background staining, then incubated in a mix containing 3µL CD3
PerCP/Cy5.5 (BioLegend 100218), 3µL B220 PerCP/Cy5.5 (BioLegend 103236), 2µL
CD11c APC (BioLegend 117310), 2µL I-A/I-E FITC (BioLegend 107616), and 1µL CCR3
PE (BioLegend 144506) per sample. Cells were identified based on forward and side
scatter characteristics and differential staining for macrophages (CD11c+), lymphocytes
(CD11c-, CD3/B220+), eosinophils (CD11c-, CD3/B220-, CCR3+) and neutrophils
(CD11c-, CD3/B220-, CCR3-). Data was analyzed using Flowjo. Validity was tested
against differential counts based on cytospins.

Analysis of mRNA expression
Right lung lobes were flash-frozen and pulverized, and total RNA was isolated
using Qiazol Lysis Reagent (Qiagen) and purified using the RNeasy kit (Qiagen). One
microgram of RNA was reverse transcribed to cDNA using M-MHV Reverse Transcriptase
(Promega) for quantitative assessment of gene expression using SYBR green (Bio-Rad).
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Expression values were normalized to indicated housekeeping genes. The primers used in
this study are listed in Supplemental table 5.

Western blot analysis
Following dissection, right lung lobes were flash-frozen for protein or mRNA
analysis. Lungs were pulverized and lysed in buffer containing 20 mM Tris·HCl (pH 8.0),
100 mM NaCl, 0.5% Nonidet P-40, 10% glycerol, and 1% protease inhibitor cocktail
(Sigma-Aldrich, P8340) (v/v), 1% phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich,
P5726, P0044) (v/v). Proteins from cell lysates were prepared in the same buffer. Insoluble
proteins were pelleted via centrifugation. Following protein quantitation of the supernatant,
samples were resuspended in loading buffer with DTT and resolved by SDS-PAGE.
Proteins were transferred to PVDF, and membranes were probed using a standard
immunoblotting protocol. Protein quantification of supernatant was determined using DC
Protein Assay (Bio-Rad, 5000116). Samples were resuspended in loading buffer with DTT
and resolved by SDS-PAGE. The quantification of protein expression was performed by
densitometry using Image Studio Lite software (LI-COR Biosciences). Antibodies used for
western blots can be found Supplemental table 6.

Image processing
Digital images were acquired using an Amersham Imager 600RGB (GE).
Photoshop (CC 2020; Adobe) and Illustrator (CC 2020; Adobe) were used to assemble the
figures. Samples were run on the same gel. When required, brightness and contrast were
adjusted equally in all lanes.
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ELISA
Lung protein samples were assayed for IL-6 (DY406, R&D), GCSF (DY414,
R&D), IL-1b (DY401, R&D), KC (DY453, R&D), and CCL20 (DY760, R&D) by ELISA
according to the manufacturer's instructions.

Non-reducing gel electrophoresis
Lung homogenates were resuspended in loading buffer without the reducing agent
DTT. A separate set of samples were resuspended in loading buffer with DTT and
incubated at 95°C for 5 minutes to reduce the disulfide bonds. The samples were resolved
by SDS-PAGE and subjected to western blot analysis as described.

PDIA3 activity assay
PDI disulfide reduction activity was monitored as previously described[3], the
reaction mixture contained 2μg MTEC lysate, 150mM DiE-GSSG (Cayman, 11547) in the
presence of 5 μM DTT. The increase in fluorescence signal was monitored at 528 nm with
excitation at 485 nm using a Synergy HTX plate reader (Biotek). The total reaction volume
was 100 μL. For inhibition of PDIA3 10ng recombinant human PDIA3 (Prospec, ENZ474) was used, the reaction mixture was incubated with LOC14 (Tocris, 5606), Eupatorin,
Eupatorin 5 Methyl Ether, or Isoquercitin (Sigma Aldrich, E4660, CDS007351) at the
indicated concentrations for 30 minutes on ice prior to the addition of DiE-GSSG. IC50s
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were calculated using GraphPad Prism (version 8.4.1, GraphPad); briefly initial rates of
fluorescence over time were determined over the first 15 minutes for indicated inhibitor
concentrations, IC50s were then determined using three-parameter non-linear regression.

Biotin Switch Assay
To block free sulfhydryls, cells were lysed in buffer containing 20 mM Tris·HCl
(pH 8.0), 100 mM NaCl, 0.5% Nonidet P-40, 10% glycerol, 1% protease inhibitor cocktail
(Sigma-Aldrich, P8340) (v/v), 1% phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich,
P5726, P0044) (v/v), and 1 mM N-Ethylmaleimide (NEM) for 1 hour at ambient
temperature. Excess NEM was then removed via acetone precipitation. Briefly, Acetone
was cooled to -20ºC. Four times the sample volume was added to protein samples. Samples
were then vortexed and incubated overnight at -20 ºC. Precipitated protein was pelleted by
centrifugation at 14,000 x g for 10 minutes. The supernatant was aspirated and the resulting
pellet was suspended in buffer containing 20 mM Tris·HCl (pH 8.0), 100 mM NaCl, 0.5%
Nonidet P-40, 10% glycerol, 1% SDS, and 1% protease inhibitor cocktail (Sigma-Aldrich,
P8340) (v/v), 1% phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich, P5726, P0044)
(v/v). Upon resuspension disulfides were reduced with 20 µM DTT and newly formed
sulfhydryl groups were labeled with 1 mM 3-(N-maleimido-propionyl) biocytin (MPB)
(Invitrogen, M1602) for 1 hour at ambient temperature. Excess DTT and MPB were
removed via acetone precipitation. The labeled lysate was precipitated using NeutrAvidin
agarose resin (Thermo Scientific, 29200) and subsequently probed using an anti-HA
antibody. As a reagent control, lysates from cells were incubated with DMSO and subjected
to the same procedures.
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Serum ALT determination
Serum ALT levels were determined using an Alanine Transaminase Colorimetric
Activity Assay Kit (Cayman, 700260).

Assay was run according to manufactures

instructions
House dust mite treatment
Human Bronchial Epithelial cells (HBEs) were plated at 4 x 105 cells and allowed
to reach 70% confluency. Cells were staved in serum free media with LOC14 for 2h.
Media was then changed dosed LOC14 and 50ug/mL HDM (Greer Laboratories,
XPB70D3A2.5). Supernatants were harvested at 24h and IL8 levels determined by ELISA.
MTECs were grown to 70% confluency then starved in serum free media dosed with 10uM
LOC14 and 25ug/mL HDM for 48h. Media was then changed containing the same
supplementation. Lysates were harvested 24h later and cytokine and chemokine levels
were determined by ELISA. Mice were anesthetized using isoflurane and treated with
25ug of HDM intranasally on day 1, 8, and consecutively on days 15-19. Mice were given
a single dose of LOC14 via interperitoneal injection. Lungs were harvested on day 20 and
cytokine levels determined by ELISA.

Statistics
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Data were analyzed by two-way analysis of variance (ANOVA) and a Benjamini,
Kreiger, and Yekutieli procedure for controlling false discovery rate, one-way analysis of
variance (ANOVA) and a Tukey’s post-hoc test to adjust for multiple comparisons, or
student’s t test where appropriate. Statistical analysis was performed using Graph Pad
Prism (version 8.4.1, GraphPad Software, La Jolla California USA, www.graphpad.com).
A p value ≤ 0.05 was considered significant. Data from multiple experiments were
averaged and expressed as mean values ± SEM.

Immunoprecipitation
HBE cells were lysed in cells were lysed in buffer containing 20 mM Tris·HCl (pH
8.0), 100 mM NaCl, 0.5% Nonidet P-40, 10% glycerol, 1% protease inhibitor cocktail
(Sigma-Aldrich, P8340) (v/v), 1% phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich,
P5726, P0044) (v/v). PDIA3 was precipitated using anti-PDIA3 antibody (Enzo Life
Sciences, ADI-SPA-585-F) and Protein G agarose beads (Invitrogen, 15920010). As a
control, lysates from cells were incubated non-specific rabbit gamma globulin (Jackson
ImmunoResearch, 011-000-002) and subjected to the same procedures. Samples were run
on reducing gels.
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FIGURE LEGENDS
Figure 1: Comparison of novel PDI inhibitors on PDIA3
A. Chemical structure of PDI inhibitors LOC14, Euparotin, Eupatorin-5-Methyl ether, and
Isoquercitin. B-D. IC50 of Euparotin, Eupatorin-5-Methyl ether, and Isoquercitin for
PDIA3 determined based on the initial rate of fluorescence formation. E. Comparison of
novel PDI inhibitors at 20µM concentration, represented as comparison to vehicle.

Figure 2: PDIA3 interacts with IAV NA
A. Western blot analysis of IAV NA:PDIA3 interaction in IAV H1N1 PR8 infected A549
cells following PDIA3 immunoprecipitation. B. Western blot analysis of IAV NAGFP:PDIA3 interaction in NA-GFP transfected A549 cells following PDIA3
immunoprecipitation. C. Western blot analysis of IAV NA levels in PDIA3 deficient
A549 CRISPR cells following infection with H1N1 PR8 or H3N2 X31, (+) and (-) indicate
presence or absence of CRISPR.

Figure 3: LOC14 treatment alters oxidative folding of IAV NA
A. Kinetics of NA catalyzed cleavage of MUNANA in the presence of recombinant NA
(rNA) and DTT treated rNA. DTT, LOC14, and LOC14 treated rNA were used as controls.
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B.

Kinetics of NA catalyzed cleavage of MUNANA from acetone precipitated

supernatants of H1N1 PR8 infected MTECs.

C.

Western blot analysis of NA

oligomerization following LOC14 treatment of H3N2 X31 infected cells, samples analyzed
by reducing (+DTT) and non-reducing (-DTT) run on an SDS-PAGE. GAPDH was used
as a loading control. D. Western blot analysis of PR8 NA infected and NA-GFP transfected
PDIA3 deficient A549 cells. GAPDH was used as a loading control. E. Western blot
analysis of thiol content of PR8 NA and NA-GFP transfected PDIA3 deficient A549 cells
by MPB labeling and neutravidin pulldown.

Figure 4: LOC14 treatment attenuates viral burden and inflammation in H1N1
infected mice.
A. Schematic representing the time points of IAV infection and LOC14 treatment and
euthanasia of mice. B. Western blot analysis of IAV HA, ATF6 50, GRP78, and GRP94 in
treated mice, b-actin was as a loading control. C. Densitometry of WCL HA and ATF6 50
normalized to b-actin. D. Analysis of mRNA for influenza PA in whole lung lysate by RTqPCR, results normalized to the geometric mean of housekeeping genes Pp1b, Rp2, and
Gapdh. E. Analysis of inflammatory and immune cells in the BALF by hema 3 stain and
differential counting. F. Analysis of mRNA for Irf7 in whole lung lysate by RT-qPCR,
results normalized to the geometric mean of housekeeping genes Pp1b, RP2, and Gapdh.
G-K. ELISA for inflammatory cytokines and chemokines from BAL fluid of infected mice.
L. Serum alanine aminotransferase levels. M. Total protein content in BAL fluid of treated
mice. *p<0.05 compared to mock groups, #p<0.05 compared to IAV-DMSO group by
two-way ANOVA. Data are expressed as means (± SEM)
119

Table 1: List of calculated IC50s in Figure 1

SUPPORTING INFORMATION
S1 TABLE: BLAST alignment of IAV neuraminidase sequences.
A. Alignment of NA sequences from various influenza serotypes. Blue color indicates
conserved Cysteine residues. (Clustal Omega v1.2.1)
S2 Fig: LOC14 treatment attenuates viral induced inflammation in H3N2 infected
mice.
Mice were treated as in Figure 4. A. Western blot analysis of IAV HA. * Indicates
nonspecific band. B-C. Analysis of mRNA for Irf7 and influenza PA in whole lung lysate
by RT-qPCR, results normalized to the geometric mean of housekeeping genes Pp1b, Rp2,
and Gapdh. D-G. Analysis of inflammatory and immune cells in the BALF by hema 3 stain
and differential counting. H-K. ELISA for inflammatory cytokines and chemokines from
BAL fluid of infected mice. *p<0.05 compared to mock groups, #p<0.05 compared to
IAV-DMSO group by one-way ANOVA. Data are expressed as means (± SEM)

S3 Fig: LOC14 may have an effect on cytokine release.
A. KC concentrations by ELISA of H1N1 infected Vehicle and LOC14 treated lung lysate
and BAL fluid. LOC14 concentration was 50mg/kg. B. KC concentrations by ELISA of
H3N2 infected Vehicle and LOC14 treated lung lysate and BAL fluid. LOC14
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concentration was 50mg/kg. *p<0.05 compared to control groups. Data are expressed as
means (± SEM)

S4 Fig: LOC14 alters cytokine levels in non-infectious HDM inflammatory models
A. IL8 concentrations by ELISA of HDM treated human bronchial epithelial cell
supernatant following treatment with LOC14. B. Cytokine and chemokine concentrations
by ELISA of lung lysate from HDM treated mice treated with LOC14. *p<0.05 compared
to control groups, **p<0.01 compared to control groups. Data are expressed as means
(± SEM)

S5 Table. List of oligonucleotides used in this study

S6 Table. List and origin of antibodies used in this study
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FIGURES

Figure 1: Comparision of novel PDI inhibitors on PDIA3
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Figure 2: PDIA3 interacts with NA
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Figure 3: LOC14 alters NA oxidative folding
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Figure 4: LOC14 treatment decreases H1N1 viral burden
C
and inflammation in vivo
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Table 1: List of calculated IC50s in Figure 1
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S1 TABLE: BLAST alignment of IAV neuraminidase sequences
Sequence ID
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Sup Fig 2: LOC14 treatment attenuates viral induced
inflammationin H3N2 infected mice
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Sup Fig 3: LOC14 may have an effect on cytokine release
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Sup Table 5: Oligonucleotide primers used in this study
Primer Name
Polymerase acidic-FW
Polymerase acidic-REV
mPP1B-FW
mPP1B-REV
mRP2-FW
mRP2-REV
mGAPDH-FW
mGAPDH-REV
mIRF7-FW
mIRF7-REV

Primer Sequence (5'-3')
CGGTCCAAATTCCTGCTGA
CATTTGGGTTCCTTCCATCC
TTTTCATCTGCACTGCCAAG
TGCAGTTGTCCACAGTCAGC
TTGCCAGCAATTCGTGTGA
CCAGTTGACCTCTTCTGACA
AGGTCGGTGTGAACGGATTTG
TGTAGACCATGTAGTTGACCTCA
GAAGACCCTGATCCTGGTGA
CCAGGTCCATGAGGAAGTGT

Sup Table 6: Western blot antibodies used in this study
Antibody
Species
IAV H1 HA
Rb
IAV H3 HA
Rb
IAV N1 NA
Sh
IAV N2 NA
Rb
PDIA3
Gt
GRP78
Rb
GRP94
Rat
ATF6
Rb
B-actin
Mouse
GAPDH
Rat

Company
Product Number
Sino Biological
11684-RP01
Sino Biological
11707-T38
R&D
AF4858
Sino Biological
40017-T60-50
LS Bio
LSB9768
Abcam
ab21685
Enzo Life Sciences ADI-SPA-850
Thermo Fisher
PA520216
Sigma
A5441
BioLegend
607902
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CHAPTER 4
DISCUSSION AND CONCLUSIONS
Overview
Viruses often have severe health and economic impacts, due to an overall
ineffectiveness of conventional therapies owing to rapid viral mutation[1]. There is an
urgent need to evaluate new targets for novel therapeutics that are less susceptible to these
mutations. Current therapies are largely targeted towards viral proteins[2], though as
obligate intracellular parasites viruses are almost entirely reliant on the host cell for
replication[3].

An increased understanding of the interplay between the virus and

subverted host biochemical pathways may provide valuable insight toward the
development of more robust antiviral therapies.

Building off earlier studies illustrating the host protein disulfide isomerase isoform
A3 (PDIA3) is directly involved in the folding of IAV proteins[4] and replication in
vitro[5], herein we show airway epithelial PDIA3 is important in the establishment of IAV
infection in vivo. We demonstrate overall PDI inhibition with the reversible PDI inhibitor
LOC14 significantly alters disulfide bonds formation of the viral surface glycoproteins
hemagglutinin (HA) and neuraminidase (NA) resulting in diminished viral burden in vitro.
Furthermore, we also show treatment with LOC14 in mice significantly decreases viral
levels and IAV induced pathogenesis in vivo.
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Current therapies
Despite the enormous impact of IAV there are currently only three classes of FDA
approved drugs to specifically combat influenza infection; NA inhibitors, M2 inhibitors,
and PA inhibitors, each one geared towards one specific influenza protein[2, 6, 7]. Both
NA and M2 are found in the viral envelope on the surface of the viral envelope and are
important in viral exit from the cell and deposition of the viral core during early infection
respectively; while PA comprises one third of the viral RNA dependent RNA polymerase
enabling viral transcription and replication in the nucleus[8, 9]. However, despite the
differences between the three proteins, both in virion localization and overall function all
three treatments suffer from similar limitations[2]. Owing to the comparatively short
generational time of viruses and the lack of a proof-reading function on the viral
polymerase the generation of drug resistant strains occurs rapidly[10]. Resistance to
Amantadine, an early M2 inhibitor, has been linked to single amino acid substitutions at
one of four positions in the transmembrane domain of the protein[11, 12]. M2 is a proton
selective ion channel required for viral replication, acidifying the interior of the virion and
facilitating conformational changes in membrane fusion proteins[9]. Strains resistant to
amantadine are so prevalent M2 inhibitors are not recommended for use[2]. Resistance to
NA inhibitors, while not as frequent nonetheless represents a significant concern[13].
Numerous countries stockpile oseltamivir, an oral NA inhibitor as part of response plans
towards pandemic influenza and is considered a first line treatment option for patients with
IAV infection[14]. Though in both seasonal influenza and during the most recent 2009
H1N1 pandemic oseltamivir resistance rapidly emerged[13]. This resistance was traced
back to a single amino acid substitution close to the active site of NA[15], this H275Y
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mutation alone is capable of decreasing the effectiveness of oseltamivir by over 400fold[16]. In addition to conferring resistance to oseltamivir, this mutation has been shown
to increase the IC50 of peramivir, a related intravenous NA inhibitor, in vitro[17]. The PA
inhibitor baloxavir represents the most recent class of anti influenza drug approved by the
FDA, the first in roughly 20 years[18, 19]. However, despite the novelty of the drug and
its mechanism of action[20], protein variants conferring resistance to baloxavir were
detected in in both its phase 2 and 3 clinical trials[21]. As in NA inhibitors, the resistance
to baloxavir stems from a single amino acid substitution[21, 22]. Thus, all the currently
approved classes of drugs suffer from low barriers to resistance.

One potential avenue around this limitation is the use of combination therapy,
utilizing antivirals with different modes of action. A combination of the M2 inhibitor
rimantadine and the broad-spectrum antiviral ribavirin has been shown to decrease the
incidence of amantadine resistance in vitro[23]. While combination therapy involving
multiple NA inhibitors found combinations of NA inhibitors dd not provide any additional
benefit over monotherapies with the same agents in vitro[24], suggesting no greater
antiviral effect than the more potent drug would be expected when combining compounds
that utilize the same mechanism.

All three classes of compounds are also limited by factors independent of viral
mutation[2]. As they target various points of the viral replicative cycle their effectiveness
is by their very nature limited to points during infection where the virus is actively
replicating. While there is some level of viral replication throughout the course of
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infection, the majority of viral replication is largely limited to the first 24 to 72h following
infection, typically peaking at approximately 48h and tapering off during the remainder of
illness[25]. The effectiveness of antivirals is significantly diminished when administered
over 48h after the onset of symptoms[26, 27], and rapid symptom onset combined with
pleomorphic presentation can make acute timely diagnosis difficult[27]. Meaning later
infection treatment is largely limited to symptomatic care rather than treatment of the
underlying etiology, especially in the case of severe influenza infection[28, 29].

Host targeted therapies
Viruses are obligate intracellular parasites and as such are almost entirely reliant on
host factors for nearly every step of their lifecycle[3]. Thus, each one of these host factors
is a potential drug target. While viral proteins can mutate rapidly, in an effort to ensure
core functionality is retained, mutations typically are limited to certain domains in an
attempt to limit the fitness cost to the virus. Host targeted therapies are by their nature less
prone to resistance than therapies targeting viral proteins, as resistance would require swift
extensive mutations to the pathogen to utilize an alternative host factor to successfully
replicate. Disulfide bonds are important for stability and functionality of both host and
viral proteins[30-32], and as such are often conserved[33]. The HA trimer is stabilized by
18 disulfide bonds, 6 per monomer[32], each one has been experimentally shown to be
required for HA functionality[34, 35]. Similarly, the mature NA tetramer contains 32
disulfides[36], again each one has been experimentally shown to be required for proper
NA function[37].
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PDIs are the major disulfide bond forming mechanism within the cell[38], and the
relationship between IAV and PDIs has been demonstrated in the literature[4, 39, 40].
PDIs represent an intriguing target for a host-based therapy due in part to the high
conservation of cysteine residues involved in disulfide bonds within influenza proteins, but
also to the large size of the PDI family. The average human protein family contains 2.5
members[41], the PDI family currently contains 21, making it almost 8.5 times larger[42,
43]. While the size of the family speaks to the importance of oxidative folding in protein
maturation and functionality, it also allows for an incredible amount of redundancy. While
not all PDIs are catalytically active there is high conservation of the CxxC active site and
extensive structural homology between members[40, 43]. Solda et al. demonstrated using
PDIA3 knockout lines that other PDIs could assist in folding PDIA3 client proteins, most
notably PDIA4, possibly owing the fact that it has three CxxC sites rather than two[4].
Additionally, they showed that certain proteins specifically require PDIA3 and no other
PDIs examined were able to assist in folding, IAV HA is one on these PDIA3 specific
proteins[4].

One major consideration in host targeted therapies is toxicity towards the host, with
therapies geared towards viral targets, generally, there is not a host equivalent process
meaning high doses of inhibitors can be given with minimal impact on the host.
Conversely, direct modulation of host processes must be more subtle as these pathways
and factors are evolutionarily conserved and required for normal host functionality. PDIA3
has been shown to be required for certain tissue development and PDIA3 knockouts are
embryonic lethal[44, 45]. However, despite the importance of PDIA3 in development,
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knockouts are generally very well tolerated on a cellular level[4, 46], illustrating the
redundancy provided by the numerous members of this family.

Additionally, the

utilization of interferon therapy, especially for the treatment of hepatitis infection
demonstrates the efficacy of utilizing host processes as antiviral therapies[47].

A particular advantage of host targeted therapies is the development of potential
broad-spectrum antivirals. Most anti-virals are specific for certain viruses, nucleoside
analogs notwithstanding. The recent Ebola and Zika outbreaks as well as the current
Coronavirus pandemic clearly demonstrate that new anti-viral compounds are few and far
between, despite an urgent need.

A recent study determined time spent in clinical

development by new anti-virals has increased dramatically despite numerous initiatives
designed to speed up access[48]. The closest SARS CoV-2 vaccine is not expected until
the end of 2020 or early 2021 despite unprecedented effort and collaboration[49], and even
then, adequate production may prove difficult. And, as previously mentioned, baloxivir is
the first new class of approved anti influenza compounds approved in nearly 20 years[19].
We have demonstrated PDI inhibition significantly impacts influenza pathogenesis and
alters viral protein maturation[39]. Influenza is not the only virus that utilizes disulfide
bonds to stabilize its proteins. Hepatitis C (HCV) virus also uses disulfides in its envelope
protein, and numerous PDIs, including PDIA3 are involved in the HCV life cycle[35, 50].
A group has shown the abscisic acid-based compound origamicin can modulate PDI
activity and blocks HCV protein folding[50]. While LOC14 has not been tested against
HCV, given its effects on PDIA1 and A3 it is not unreasonable to assume that it would also
alter HCV protein folding, though experimentation is needed to determine with any
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certainty. Nonetheless, two very different viruses infecting two very different tissues are
impacted by the same mechanism[39, 50-52]. The spike protein of SARS CoV-2 as well
as SARS-CoV and MERS-CoV, the two other coronaviruses with significant pandemic
potential, are also stabilized by disulfide bonds[40, 53]. Large amounts of unpaired
cysteines in the spike protein of SARS-CoV are believed to assist in binding with the ACE2
receptor, the authors speculate the unpaired cysteines may in fact play a role in SARS-CoV
crossing host barriers[54]. In addition to adding disulfides to protein PDIs are also capable
of removing unwanted extraneous disulfides from proteins as well through reductive
unfolding of the nascent polypeptide[55]. While the exact nature of PDIs in the maturation
of this protein are not currently known, PDI inhibition warrants further investigation as an
anti-coronavirus strategy, especially in the context of the current pandemic.

While targeting host processes subverted by viruses are less prone to resistance, it
is still possible for the virus to mutate around these restrictions. HIV envelope glycoprotein
contains 10 conserved disulfide bonds, only five of which are responsible for folding, and
eight for proper functionality[34]. Demonstrating the possibility that certain viral proteins
may have remarkable tolerance to the manipulation of its tertiary structure. Further work
by the same group demonstrated one particular disulfide bond required for folding,
C385/C418, could be replaced by the acquisition of local features within the beta barrel,
primarily the condensation of amino acid sidechains to increase local interactions[56]. It
should be noted, however, that HIV is the prototypical fast evolving virus, and is known
for its high genetic variability. HIV produces every possible single base substitution within
a patient multiple times every day[57]. While host targeted therapies have a higher barrier
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to resistance than viral targeted therapies, given short generation times and error prone
replication mechanisms[10], these barriers can be overcome.

Upon infecting the cell influenza is sensed through intracellular pattern recognition
receptors RIG-I, MDA5, or various Toll-like receptors (TLRs)[51], upon stimulation these
sensors trigger the activation of the NF-kB and interferon pathways activating cellular
antiviral responses[58]. These pathways lead to the expression of pro-inflammatory
cytokines like IL-1, IL-6, and TNF-a, and chemokines to cause rapid influx of
inflammatory cells to the lung[59]. While a robust inflammatory response in necessary for
control of the virus it can cause unwanted damage to underlying tissues, leading to
decreases in lung function[60, 61]. Normally these responses are self-limiting over the
course of infection, though rarely during the infection with seasonal influenza strains and
more commonly with pandemic and highly pathogenic strains these responses can lead to
a positive feedback loop resulting in aberrant immune activation and systemic cytokine
signaling resulting in severe tissue damage and inflammation, termed cytokine storm[62].
The exact causes of cytokine storm are not currently well understood[62]. Current
therapies are not considered directly immunomodulatory, though by diminishing viral
levels they can result in decreased immune responses, they are not given to directly lower
inflammation[2]. Even in the absence of cytokine storm lung damage from the host
inflammatory response is a significant cause of mortality[51]. For this reason, compounds
directed toward excessive proinflammatory host immune responses have been proposed
for use in conjunction with antiviral therapies.
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Statins are low cost, potent anti-inflammatory compounds though combination
therapies involving them has yielded mixed results[63]. One study showed a combination
simvastatin and oseltamivir did not improve efficacy over oseltamivir treatment alone in
mice infected with lethal doses of avian H5N1[64]. Whereas a separate study investigating
a triple cocktail of oseltamivir, fenofibrate, and simvastatin showed improvement over
oseltamivir monotherapy[65]. Interferon therapy has been classically used to treat viral
infections, especially HCV[47], as well as other conditions such as cancer and autoimmune
disorders, and results in potent immune suppression[66]. However, interferon therapy is
commonly associated with severe and varied side effects[66, 67]. Glucocorticoids are
commonly used concurrently with conventional antiviral therapies to treat acute respiratory
distress syndrome (ARDS) and influenza associated pneumonia[68]. They act through the
glucocorticoid receptor and ultimately lead to the down regulation of proinflammatory
genes while simultaneously upregulating anti-inflammatory genes. Though their use has
been associated with increased duration of viral replication in certain patients. And
observational studies during the 2009 H1N1 pandemic found systemic glucocorticoid
treatment was associated with increased secondary infections and higher mortality in
intensive care unit patients[69]. While the control of aberrant or excessive immune
responses represents a valuable tool in curbing morbidity and mortality associated with
influenza infection care must be taken to avoid compromising the body’s ability to
adequately control viral replication. There are other potential complications to consider
with combination therapies such as the route of administration, availability of the drug,
complexity of the dosing regimen, and potential drug interactions.
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We show treatment with the reversible PDI inhibitor LOC14 has direct anti-viral
effects, altering the maturation of viral proteins by impacting oxidative folding[39]. We
also demonstrate LOC14 treatment has a separate anti-inflammatory effect, though the
exact mechanism needs to be more thoroughly investigated. Previous work in the lab has
shown siRNA mediated knockdown of PDIA3 in C10 lung epithelial cells altered oxidative
folding of eotaxin[5], a chemokine important in the selective recruitment of eosinophils to
inflammatory sites[70]. Interestingly, we show discrepancies between cytokine levels of
certain proinflammatory markers in the BAL fluid and the lung homogenates of IAV
infected mice following PDI inhibition.

Levels of KC, CCL20, and IL-6 that are

significantly decreased in the BAL remain elevated in the lung tissue, suggesting a possible
decrease in the release of these cytokines and chemokines. Generally, proteins that do not
properly fold aggregate together and are retained within the cell and do not proceed
normally through the secretary pathway[38]. While further experimentation is needed to
determine the nature of this retention within the cell, the previously demonstrated role of
PDIA3 in eotaxin maturation[5] and the effect of LOC14 suggest defects in oxidative
folding are likely a contributing factor. That we do not observe this effect in other
cytokines may also demonstrate a role in other PDIs in their maturation, though again
further experimentation with siRNA knockdowns of additional PDIs or additional PDI
inhibitors more specifically targeted towards other members of the PDI family.

Coagulation cascade
Coagulation is highly ordered intricate process involving endothelial cells, blood
platelets, and various clotting factors[71]. While there are numerous pathways, the
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mechanism generally involves the activation and aggregation of platelets and the
accumulation and maturation of fibrin, resulting in a clot[71, 72]. Anticoagulants control
the coagulation process and help to limit thrombus propagation[73]. Viral infections are
commonly associated with coagulation disorders and they can affect the coagulation
pathways in a variety of ways[74]. Experiments in C57BL/6 mice have demonstrated IAV
infection activates coagulation through the increased generation of thrombin and fibrin
deposition[75].

The H1N1 2009 pdm09 strain has been reported to cause both

hemorrhagic and thrombotic complications[76], while both H7N9 and H5N1 strains have
been found to cause coagulopathy[77, 78]. Influenza induced overactivation of coagulation
is linked to an increased risk of various cardiac and pulmonary diseases like pulmonary
embolism and myocardial infarction[79, 80]. And oseltamivir treatment has demonstrated
decreases in viral loads are associated with decreases in the incidence of cardiac
complications[81]. Influenza infection can lead to the depletion of anticoagulant factors
by the induction of a pro-thrombotic state[82]. This exhaustion of anticoagulant elements
can in turn lead to abnormal coagulation and hemorrhage which is commonly seen in
patients with severe IAV infection and cytokine storm[83]. PDIs, primarily PDIA1[84]
and A3[85], play critical roles in the early activation of the coagulation cascade. Given
their roles in early activation much attention is being given to PDI inhibitors in an attempt
to determine if they can help abate aberrant thrombosis. One study has shown PACMA31
treatment inhibits both platelet deposition and fibrin formation in a mouse model of
stenosis in the inferior vena cava[86]. Others have shown 16F16 blocks tissue factor
activation, though these results are somewhat inconsistent[87]. The effect of LOC14 on
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coagulation has not been explored, but given its demonstrated effects on viral pathogenesis,
it would be interesting to explore.

Secondary bacterial infections
Secondary bacterial infections commonly associated with influenza infections,
most notably with pandemic influenza strains[88].

Haemophilus influenzae was so

frequently found in patient samples during the 1918 H1N1 pandemic it was originally
believed to be the causative agent until the early 1930s[89]. While the exact causes of
secondary bacterial infection are not completely understood it is currently thought a
combination of viral damage to the lung epithelium providing the bacteria with an
enhanced niche and a shift of the immune system towards antiviral activity rather than
antibacterial activity may play a role[88]. Up to 75% of those that acquire influenza
associated pneumonia are confirmed to have bacterial coinfection[90]. During the recent
2009 H1N1 pandemic pneumonia as a result of secondary infection was found in almost
50% of mortalities[91]. Not surprisingly immunosuppression is associated with increased
susceptibility to secondary bacterial infection[92]. Secondary infection is typically treated
with antibiotics in conjunction with conventional antivirals[93]. However, with antibiotic
resistance becoming increasingly prevalent and limitations in the current dosing of antiinfluenza drugs novel treatments may be required. Disulfide bonds are important in both
prokaryotic and eukaryotic proteins, and bacteria, like eukaryotes have evolved a system
to aid in their formation[94]. Bacteria utilize the Dsb family of proteins to catalyze
disulfide bond formation, this family has four members, DsbA, B, C and D which behave
much like the PDI family of proteins[94]. In fact, like PDIs, these proteins contain
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thioredoxin like domains and utilize the same CxxC active site architecture[43, 94]. The
conservation of the active site suggests that PDI inhibitors like LOC14 may also inhibit
these proteins, though further experimentation is needed. There are currently small
molecule inhibitors of Dsb proteins available, most notably for DsbB, which plays a role
akin to Ero1 in eukaryotes and acts a primarily as a recycling enzyme for DsbA, though
DsbB has no direct homologs[95]. These compounds decrease virulence, and some are
being explored as potential antibiotics[95, 96], though none have been tested in the context
of bacterial infection secondary to influenza.

Potential pitfalls and considerations
While we have established PDIA3 plays an important role in IAV infection further
experimentation is required to elucidate its exact role in pathogenesis. Though PDIA3 is
known to assist in the oxidative folding of viral proteins, mass spectrometry experiments
would help determine exactly which disulfides are catalyzed specifically by PDIA3. This
could provide valuable insight on HA/NA maturation and glycoprotein folding in general.
Moreover, further characterization of the virus itself by examination of viral titers
combined with detailed structural analysis by electron microscopy under PDIA3 deficient
conditions could shine additional light on the role of PDIA3 in the viral lifecycle. Along
the same line histopathologic analysis of infected tissues and pulmonary function analysis
following PDI inhibition would be useful in evaluating PDIA3 as a pharmacological target.
At present, no specific PDIA3 inhibitors are available, though there are several plant
flavonoid compounds have been identified as potential inhibitor candidates that are more
targeted towards PDIA3 as opposed to other members of the PDI family[97]. The use of
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these compounds as well as other newly identified PDI inhibitors would prove useful in
determining PDIA3’s role, as well as the role of other PDIs in IAV infection.

We deliver LOC14 systemically via intraperitoneal injection, though the evaluation
of a more targeted delivery method, such as intratracheal injection or oropharyngeal
delivery may allow the same antiviral effects at a lower dosage.

Similarly,

pharmacokinetic studies would provide insight on the distribution, absorption, and
metabolism of LOC14, which could lead to the refinement of dosing regimens and
concentrations. Further studies on the interaction of LOC14 with PDIA3 specifically,
along with other PDIs may also help to improve these regimens.

Additionally, we have focused solely on the oxidoreductase activity of PDIA3;
however, it is a multifaceted protein that plays numerous roles within the cell[40, 98]. It
has been demonstrated to be a critical part of the peptide loading complex (PLC) of MHC
class I, which is an important part of the anti-viral immune response[99]. While it has been
shown that the redox activity of PDIA3 is dispensable for its role in the PLC it is not known
what effect PDI inhibition will have on MHC class I signaling[98]. However stable
knockout PDIA3 cells do not show defects in MHC class I activity[46]. Similarly, PDIA3
can act as a receptor for vitamin D3, acts in cell migration, as well as apoptosis[98]; any
one of which may play an important role in active viral infection beyond oxidative protein
folding.
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Disulfide bonds are utilized by many viruses to impart stability in their proteins,
particularly glycoproteins. Various respiratory syncytial virus (RSV)[100], coronaviruses
(CoV)[40], HIV[34], and HCV[35] proteins contain disulfide bonds, though their reliance
on host PDIs in their formation is not currently known in all cases. HIV is known to require
PDIA1 activity to enter cells[101]shuffling disulfide bonds of envelope proteins to
facilitate viral entry. As mentioned above, PDI inhibition with origamicin can block HCV
protein folding[50]. And PDIA3 inhibition through nitazoxanide, a thiazolide, has been
shown to block F-protein folding[102]. Intriguingly, nitazoxanide has also demonstrated
antiviral activity against HCV, rotavirus, and IAV[102]. Additional experimentation could
determine if the utilization of host PDIs is a common strategy employed by other viruses
and thus a promising target for future broad spectrum anti-virals. However even if host
PDI utilization is limited to a few select viruses, PDI inhibition still warrants further
investigation for its anti-inflammatory and potential immunomodulatory effects which may
have a beneficial role in viral treatment.
Another important consideration is our model usage, most of the work presented is
in a mouse model of influenza infection or in isolated primary mouse epithelial cells. While
mice are common models of human diseases and conditions, they can often respond to
stimuli drastically differently than do humans[103]. Mouse hemoglobin has a lower
affinity for oxygen than does human hemoglobin, supporting the higher rodent
metabolism[104]. Action potentials in neurons are known to be shorter in mice than
humans[104]. There are also differences in the immune system of the two organisms[105].
The PDIA3 gene is located on chromosome 2 in the mouse while it is present on
chromosome 15 in humans, this can lead to differences in regulatory sequences and overall
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gene expression which can have profound effects on the protein itself. While utilizing
isolated human primary cells is a potential solution, they too are not without issues as
typical cell culture techniques can also lead to differences in gene expression from that of
the original organism. This may be avoided by the use of human organoids, self-organizing
tissues derived from isolated stem cells[106]. These organoids develop more or less as
normal and recapitulate typical organ architecture[106]. Focusing specifically on the lung,
numerous techniques exist to allow for the differentiation of airway-like structures
containing different cell types[107]. And these cultures have been already utilized to
monitor influenza infection in vitro[108].
A final consideration is the nature of drug discovery and development itself, which
fails far more often than it succeeds. Briefly, the development process proceeds from basic
research, to preclinical development, to actual clinical trials, and finally FDA approval;
though the actual process is much longer, difficult, and complex[109]. The average time
for the development of a novel antiviral is roughly 6 years[109], though as we are utilizing
a host process as a target rather than a unique viral protein this time frame would
undoubtably be increased due to the associated complexities Our work is firmly in the
basic research phase of the process, as there is still much we do not know about how LOC14
behaves in mice, much less humans.

Conclusion
PDIs play important roles in influenza infection, from direct utilization by the virus
to the host response to infection. And their inhibition represents a novel target for the
potential development of future antivirals at a time when we are woefully underprepared
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to manage the emergence of new zoonotic viruses or novel pandemic strains of influenza.
As a host targeted therapy PDI inhibition with small molecule inhibitors set up a high
genetic barrier to resistance potentially circumventing rapid viral mutation. Moreover, the
use of various PDI inhibitors in numerous animal models of disease illustrates that they are
generally well tolerated[110-112], possibly due to the redundancy built into the PDI family.
Likewise, by targeting a system utilized by both the host and virus we have the potential to
generate a broad-spectrum antiviral compound that mediates its effect on different fronts.
However, further investigation and analysis is needed to determine proper targeting and
dosing to avoid potential cytotoxicity or off target effects, potentially worsening the
infection. Despite these limitations and concerns PDI inhibition with LOC14 represents
an intriguing platform for the development of potential future anti-virals.
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